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ABSTRACT 
 
Molecular Studies of Avian Leukosis Virus. (December 2005) 
Blayne Myron Mozisek, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. John El-Attrache 
 
 It was nearly a century ago that the viral etiology of sarcomas and leukemia 
(leukosis) in the domestic fowl was first described by Ellerman and Bang, working in 
Copenhagen, and Rous in New York. Through the following decades, in an attempt to 
control these oncogenic diseases which were becoming the main cause of mortality in 
commercial poultry, extensive investigation in many veterinary laboratories was 
undertaken. Throughout this period and continuing today, advancements in our 
understanding of the mechanisms of these viruses are ever expanding. This knowledge has 
exponentially expanded since the discovery and in turn the development of molecular, 
nucleic acid-based tools to analyze and interpret these viral genomes. This burgeoning 
field of research has shed light on countless topics including the elucidation of specific 
viral mechanisms of neoplastic induction. It has allowed for the creation of diagnostics 
which are vastly superior in sensitivity and specificity than to their non-molecular-based 
counterparts, and in the future will lead to the generation of disease resistance in the host. 
These topics, in specific regard to molecular studies of avian leukosis virus, will be further 
developed in this thesis.  
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INTRODUCTION 
Retrovirus classification 
 The family Retroviridae encompasses an extensive and diverse group of viruses 
found in all vertebrates (120). The earliest of these viruses studied were isolated from birds 
and mice. Examples of such retroviruses include avian leukosis virus (ALV), Rous 
sarcoma virus (RSV), mouse mammary tumor virus (MMTV), and murine leukemia virus 
(MLV). These viruses were the subject of intense study due to their propensity to form 
neoplastic disease in their host organisms. Investigations into the mechanisms by which 
these viruses were able to cause tumors eventually led to the discovery and development of 
the oncogene theory of tumorigenesis: the elucidation of oncogenes within their viral 
genomes or their interaction with host oncogenes following infection/integration in a direct 
or indirect way to contribute to tumor formation (49, 116). 
 As science progressed other viruses were isolated that shared common  
 
characteristics with the retroviruses described above, such as genome organization and  
 
replication strategies. Historically, these viruses were further classified into three  
 
subfamilies based on their patterns of pathogenicity: 1) the acutely oncogenic  
 
retroviruses, or oncoretroviruses; 2) the lentiviruses (associated with “slow” diseases or  
 
those with long latency periods); 3) and spumaviruses (“foamy” viruses, named because  
 
of the pathognomonic changes observed in infected cells) (19). Until recently these  
 
viruses were grouped as mammalian type B-D, avian type C, human T-cell leukemia  
 
________ 
This thesis follows the style of the Journal of Virological Methods. 
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virus / bovine leukemia virus (HTLV/BLV) type retroviruses, lentiviruses, and  
spumaviruses. The categories were based on electron microscopic (EM) appearance of 
their nucleocapsid structures, host range, and pathogenicity (19). Further study of these 
viruses enabled detailed comparison of their genomic structures and nucleic acid 
sequences, which resulted in further refinement of the retrovirus taxonomic classification 
system in use today and displayed in Table 1 (120).  
Table 1. Retrovirus genera. 
Retrovirus Class   Examples Morphology 
Alpharetrovirus  Avian leukosis virus (ALV) C-type 
  Rous sarcoma virus (RSV)  
Betaretrovirus   Mouse mammary tumor virus (MMTV) B-, D-type 
  Mason-Pfizer monkey virus (MPMV)  
  Jaagsiekte sheep retorvirus (JSRV)  
Gammaretrovirus   Murine leukemia virus (MLV) C-type 
  Feline leukemia virus (FeLV)  
  Gabbon ape leukemia virus (GaLV)  
  Reticuloendotheliosis virus (RevT)  
Deltaretrovirus   Human T-lymphotrpic virus (HTLV)-1, -2 --- 
  Bovine leukemia virus (BLV)  
  Simian T-lymphotropic virus (HTLV)-1, -2, -3  
Epsilonretrovirus   Walleye dermal sarcoma virus --- 
  Walleye epidermal hyperplasia virus 1  
Lentivirus   Human immunodeficiency virus type 1 (HIV-1) Rod/cone core 
  HIV-2  
  Simian immunodeficiency virus (SIV)  
  Equine immunodeficiency virus (FIV)  
  Caprine arthritis encephalitis virus (CAEV)  
  Visna/maedi virus  
  Feline immunodeficiency virus (FIV)  
Spumavirus   Human foamy virus (HFV) Immature 
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Retrovirus genetics and proteins 
The retrovirus genome is referred to as being “pseudodiploid” due to the two 
identical single-stranded positive sense RNA molecules which comprise its genetic 
material (19).  The genetic material of the virus can be described in two different fashions, 
virion associated RNA or either proviral DNA (Figure 1).  
 
Figure 1. Both viral RNA and proviral DNA genome structures of a prototypical retrovirus. The 
genomic viral RNA, represented by a single black line, is shown at the top of the figure, with the 
structure of the resulting provirus after reverse transcription below. The locations of the open reading 
frames gag, pol, and env are shown. Reverse transcription of the RNA results in rearrangemnet of the 
termini of the genome, resulting in the structures of the LTRs (long terminal repeats) as indicated. 
The 5’ end of the genomic RNA begins with the “r” (for repeat) and “u5” (for 
unique 5’ region) segments, followed by the viral genes gag, pol, and env. The 3’ end of 
this sequence is terminated by the u3 (for unique 3’ region) and r (identical to the 5’ 
region) regions and a polyA tail. The virus then uses its prepackaged replication enzymes 
to convert this RNA molecule into a double-stranded DNA molecule via reverse 
transcriptase, from which it is then integrated into the host cell chromosomal DNA , where 
it is then referred to as a “provirus”(119).  
Terminating the ends of the proviral DNA are the long terminal repeats (LTRs), 
which contain the regions U3, R, and U5. The mechanisms utilized for reading and 
translating the viral RNA during reverse transcription cause the u3 and u5 regions to be 
duplicated such that the 5’ and 3’ ends of the proviral DNA differ from that of the viral 
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RNA genome (54). This rearrangement and resulting formation of the LTRs at both ends 
of the genome enables appropriate expression of the viral genes (54). The U3 region of the 
5’ LTR contains the viral promoters and enhancers responsible for initiation of 
transcription of the viral genome at the 5’ U3/R junction (69) . Yielding the viral gag and 
pol genes, expressed from an unspliced transcript, while the env gene is expressed from a 
spliced transcript (54). A termination signal is located at the 3’ end of the genome along 
with the polyadenylation signal in the 3’ LTR (54). The viral core structural proteins are 
encoded by the gag gene; these include the matrix (MA), capsid (CA), and nucleocapsid 
(NC). Within the reading frame of the gag gene some retroviruses also encode small 
regulatory proteins or peptides. The viral replication enzymes are encoded by the pol gene 
and these include both reverse transcriptase (RT) and integrase (IN). The env gene encodes 
the envelope (Env) glycoprotein which is post-translationally cleaved to form the 
transmembrane (TM) and surface (SU) subunits (78).  
Virion structure 
The mature retrovirus particle consists of a viral protein core, surrounded by a viral 
envelope made of cellular membrane-derived lipid bilayer and the viral encoded globular 
SU, 85 kD glycoprotein gp85, which mediates binding to the cellular receptor and a 37 kD 
TM glycoprotein anchor subunit that mediates fusion (69, 148). The cellular constituents 
of the envelope are acquired by the virus as it is assembled and buds from the infected 
cell’s outer membrane (69). The structural core of the virion contains two copies of the 
positive sense RNA genome, found as a dimer and associated with the nucleocapsid 
protein, that is in turn shelled by the capsid protein (19). As described above, in addition to 
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the genome, retroviruses package within their core a unique set of enzymes, reverse 
transcriptase, protease, and integrase, enabling them to replicate through a double-stranded 
DNA intermediate. Outside the viral capsid is a matrix protein that appears to assimilate 
with the inner wall of the viral envelope (69). Newly budding immature viral particles 
contain the unprocessed Gag and Gag-Pol precursors of the proteins that will eventually 
make up the mature virus. The morphology of these immature particles is spherical, with a 
characteristic electron-lucent center (54). At maturation, viral proteins are processed and 
cleaved causing structure and morphology to change drastically (155). The mature particle 
retains its spherical shape to form a viral particle of approximately 100nm in diameter, but 
size in given preparations are not highly homogeneous (69). The glycoprotein surface 
projections are approximately eight nanometers in diameter (26). Virions exhibit a buoyant 
density in sucrose in a range of 1.16 to 1.18 g/mL and a sedimentation rate of 
approximately 600 S (54). The mature enveloped virions are sensitive to heat, detergents, 
and formaldehyde, while being somewhat resistant to UV light (54).  
Endogenous retroviruses 
Utilizing the proteins described above and the host cell replication scheme, viruses 
of the family Retroviridae have devised a unique method of perpetuating their genome. 
The incorporation of their genetic material into their hosts’ chromosomal DNA, as 
described previously, has allowed for the continuance of a subset of these viruses to be 
transferred from host to host via Mendelian genes. Unlike the exogenous ALVs which are 
transmitted by conventional means through both vertical and horizontal transmission, a 
process that requires infectious virus; endogenous viral (ev) genes are inherited as host 
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genes and may or may not be expressed (30). Partial expression of ev genes can lead to one 
of the following phenotypes: 1) expression of viral group-specific (gs) antigen and 
subgroup E viral envelope antigen; 2) expression of subgroup E viral envelope antigen; 
and 3) spontaneous production of infectious subgroup E virus (41). Fully infectious 
endogenous viruses can be transmitted congenitally, horizontally, or genetically (41). 
These endogenous retroviruses have been reported in six classes of vertebrates  and have 
become the subject of intense investigation (66). Of particular interest are the mammalian 
and avian endogenous retroviruses (AERs). This interest stems in large part from the 
recent finding that AERs were a contributing factor to the emergence of a novel, highly 
infectious subgroup of ALV, subgroup J (148). To date, three groups of AERs have been 
described: 1) the ev loci, 2) the endogenous avian retrovirus family (EAV), and 3) the 
avian retrotransposons (ART-CH) (11). The best characterized of these endogenous 
sequences are the evs. Within the genome of the White Leghorn chicken 21 of these 
viruses have been described (3, 27, 67, 134). Some of these viruses encode for and express 
functional envelope glycoproteins, such as ev-3 and ev-6, while others such as ev-1, are 
classified as transcriptionally silent (8, 62, 63).  Several non-defective evs also exist which 
are able to produce infectious virus, such as ev-2 (11). Regardless of the ev, all which 
possess the env gene exhibit a common subgroup specificity designated E, as previously 
described. The sequence homology of this gene within all the subgroups of ALV expresses 
an identity of approximately 85-90% (11). While these endogenous viral sequences have 
been described in nearly all types of chickens, animals have been breed and selected to 
lack all known ev loci; these animals are referred to as ev-0 lines. 
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The ancient EAVs were the second class of endogenous viruses to be described 
(15, 16, 37). The identification of this group of endogenous virus was first made by low-
stringency hybridization of ev-0 cell DNA with avian leukosis-sarcoma virus (ALSV) 
probes which revealed the presence of approximately 50 copies of EAV per genome in 
many avian species, including the White Leghorn chicken and the red jungle fowl, the 
progenitor of the domestic chicken (11). Of the described EAV loci, none appear to give 
rise to infectious virus and only one, E51, contains what appears to an intact env gene; all 
others include deletions of all or part of the SU. As a result, the description of a EAV 
functional envelope protein has not occurred and their subgroup specificity remains 
unknown (11).  
Present at approximately the same rate as the EAVs within the chicken genome are 
the thirds class of endogenous viruses, the ART-CH (59, 94). These are comprised of 
small, ~3kbp, loci that include relatively short regions that show similarity to the ALSV 
genome. The ART-CH are transcriptionally active and have the potential to translate 
portions of the gag gene, although no protein product encoded by these elements has been 
described to date (12).   
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AVIAN LEUKOSIS VIRUS 
Overview 
Over the last century the body of literature accumulated and the wealth of 
knowledge discovered concerning the ALVs may perhaps make them the most well 
studied and mechanistically illuminated of the retroviruses. Henceforth, this group of 
retroviruses is the focus of the research performed under the direction of this thesis.   
These viruses in chickens are grouped into the Alpharetrovirus genus and are 
classified into five pathogenic subgroups: A, B, C, D, and most recently J (106). Their 
distinctions arise from differences in envelope glycoproteins, virus-serum neutralization 
tests, virus interference, and host range (71). Of these exogenous subgroups, A and B are 
the most common ALVs, while subgroups C and D have been rarely reported in 
commercial poultry due in large part to the eradication efforts of the commercial poultry 
industry (21, 108). Chickens infected with exogenous ALV shed virus into albumen of 
eggs, vaginal and cloacal secretions, and congenitally transmit virus to the next generation. 
As described earlier, this group of avian retroviruses are best known and most studied due 
to their propensity to cause neoplastic disease, inducing leukosis affecting the erythroid, 
lymphoid, and myeloid series of hematopoietic cells, in addition to a number of solid 
tumors, including those affecting the mesenchyme, kidney, ovary, testis, liver, pancreas, 
and nervous system (10, 108, 117). These pluripotent neoplasms of ALVs cause severe 
economic losses due to condemnations at slaughter, loss of pedigree birds, and tumor 
mortality.  
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Neoplastic disease 
The knowledge gained since the first isolation of ALVs has greatly contributed to 
the understanding of the molecular mechanisms responsible for many neoplastic 
conditions. Understanding these mechanisms has allowed the causative ALV to be placed 
into two categories, slowly or acutely transforming. The slowly transforming ALVs have a 
genetic structure like that of most typical retroviruses, that is their RNA genome is 
arranged in the 5’-gag-pol-env-3’ format. The tumors they induce, as their name implies, 
are late onset, forming several months (~3) after initial infection. The mechanism by which 
these viruses are able to induce neoplastic disease, in particular lymphoid and erythroid 
leukosis (erythroblastosis) has been correlated to their proviral insertion upstream, 
downstream, or within host proto-oncogenes. Following this proviral integration the 
promoter/enhancer capacity of the viral LTR initiates the transcriptional up regulation of 
the host proto-oncogene, eventually leading to neoplasia (54). The determination of the cell 
type to be transformed is believed to be due to specific viral LTR sequences and the 
presence of specific LTR binding proteins on the cell (107).  
The genetic composition of the acutely transforming ALVs is nearly identical to 
that of their slow transforming counterparts, with the exception of an oncogene or two 
within their genome. These oncogenes have been acquired by the virus through 
transduction of host oncogenes during the retrovirus replication process. These oncogenes 
can occur in variable locations within the viral genome and often lead to deletions within 
the structural genes of the virus such that the oncogene-carrying virion is replication 
defective and needs a replication competent helper virus to counter the genetic defect. 
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These ALVs are termed acutely transforming because they can induce neoplastic disease in 
their target cells, both in cell culture and in vivo, in a matter of a few days (39, 56).  Fifteen 
of these avian viral oncogenes have been described (119). Their sequences are not 
completely homologous to their cellular counterparts and neither are the proteins they 
encode (107). These gene products, uncontrolled by normal regulatory processes, alter 
pathways of the cell concerned mostly with cell growth and differentiation. These 15 
oncogenes can be placed into four main categories: growth factors, growth factor receptors, 
nuclear factors, and signal transducers. 
The alteration of homeostatic expression of the Myc transcription factor is 
associated with a number of human and animal cancers (65). This transcription factor 
controls cell functions such as proliferation, differentiation, and apoptosis, through 
activation and repression of a number of target genes (58). These Myc regulated genes 
include those involved in angiogenesis, metabolism, and cell cycle and growth (28, 90). 
The function of Myc to influence cell cycle regulatory genes is thought to be important in 
its ability to induce of cell growth and proliferation (103). The over expression of Myc has 
also been shown to inhibit cellular differentiation, perhaps through its ability to block the 
cell cycle exit (65). In addition, Myc can also sensitize cells to apoptosis  and it effectively 
induces blood vessel growth in a number of tumor models (17, 89, 93, 113). As explained 
earlier, ALV integration within the c-myc gene  in immature B cells can result in metastatic 
bursal lymphomas (64, 91). Examination of the proviral integration within these neoplastic 
lymphoid cells show that nearly all proviruses have under gone deletion of the 5’ LTR (82, 
83), in turn allowing the 3’ LTR to induce high levels of c-myc gene transcription (75). 
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These cells of the bursa, originating from approximately two stem cells that establish 
follicles during embryonic hemtaopoeisis, grow to number approximately 10,000 mature 
follicles (151). Upon infection at an early stage transformed or hyperproliferating follicles 
feature clonal proviral c-myc integration. These transformed follicles are filled with Myc-
overexpressing lymphocytes which can be identified by their differential staining with 
methyl green pyronin (MGP), which indicates their increased ribosomal content (29). Of 
the 5 to 20 follicles which may be transformed, only one or a few of these 
hyperproliferating follicles progress to form a metastatic lymphoma after 3 months of age, 
presumably after additional mutations and/or proviral integration next to other proto-
oncogenes(24, 144). 
 ALV has also been shown to induce erythroblastosis by mechanisms similar to 
those which cause ML, by integration of proviruses near another host oncogene, c-erbB.  
This cellular oncogene was first discovered due to its close amino acid homology with 
portions of the human epidermal growth factor receptor (EGF) which were strikingly 
similar to the oncogenes carried by the acutely transforming avian erythroblastosis virus 
(AEV) (147, 152). Data has shown that upon activation, c-erbB can assume an oncogenic 
role similar to that of its viral counterpart. Although, no alteration of c-erbA  (the cellular 
homolog of the other oncogene of AEV) was found in leukemic samples analyzed (118). 
Furthermore, in the study of these leukemic samples, transcription of c-erbB but not c-erbA  
was highly elevated, suggesting that activation of the c-erbB gene alone is sufficient to 
cause erythroblast formation (118).  The c-erbB oncogene encodes the EGF receptor, a 
protein kinase which is involved in growth signaling in many cell types, hemopoiesis, and 
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formation of transforming growth factor α (TGFα) (95, 100, 104).  The EGF receptor 
contains three domains, an extracellular EGF binding domain, a short transmembrane 
domain, and a  cytoplasmic domain (70). Interestingly, upon ALV infection most of the 
proviral integrations from tumors map within the 3’ region of c-erbB intron 14, so that a 
truncated gag-env-erbB fusion protein is produced which is thought to have constitutive 
kinase activity (46, 86, 95, 118).  These fusion products generally retain the complete 
provirus, and are generated by transcription read-through past the 3’ LTR followed by 
alternative splicing (86, 95). From these fusion products and in turn read-through 
transcripts, recombinant viruses arise containing transduced c-erbB, forming acutely 
transforming viruses which can be observed in approximately 50% of the erythroblastosis 
tumors that arise (86, 95).  Of those proviruses analyzed after initial infection, all were 
inserted in the same transcriptional orientation as c-erbB, and elevated expression of c-
erbB related mRNA was consistently observed (51, 118). The c-erbB oncogene activated 
in this manner has lost the majority of its extracellular domain, but retains an intact 
intracellular domain (95). This molecule is strictly leukemogenic and can develop 
sacromatogenic potential only after accumulation of additional mutations in the kinase or 
C-terminal regulatory domain. Raines et al. observed that the truncated, structurally altered 
transcripts of c-erbB show a 100% correlation with the development of erythroblastosis, 
suggesting that disruption of the c-erbB locus is important for oncogenesis (114, 115, 118). 
As described, examinations of ALV proviral integration sites within the c-myc or c-
erbB genes of tumors has revealed a non-random pattern of proviral integration, giving 
insight to the oncogenic mechanisms of ALV. The integration of the ALV proviral DNA 
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into c-myc has been shown to cause bursal lymphomas, and predominantly this insertion 
occurs within the 3’ region of c-myc intron 1 (122, 130). With the c-myc protein-coding 
sequence beginning in exon 2, the promoter/enhancer capabilities of the ALV LTR 
sequence have been shown to increase c-myc mRNA and protein roughly 50-fold (87). The 
integration of c-erbB observed in erythroblastosis are also non-random, so that the majority 
of tumors show integrations clustered within the 300 bp region of intron 14 (55).  
Integration and replication 
 The replication of ALV is much like that of other retroviruses, with the exception 
of specific receptors used for attachment to the target cell by specific subgroups (69). The 
scenario described here is that of a replication competent virus, i.e. one that has not 
undergone transduction of cellular oncogenes and in turn, deletion of necessary structural 
genes. The first step in ALV infection, as with all other viruses, involves attachment to the 
host cell plasma membrane. This process is mediated by the interaction of the viral 
glycoproteins extending from its surface and specific receptor(s) on the host cell.  
Subsequent fusion of the viral envelope with the cellular plasma membrane occurs, either 
directly or following endocytosis, which results in the release of the viral core into the 
cytoplasm of the cell (26). In the case of ALV subgroup A (ALV-A), a small molecule 
with a single transmembrane domain distantly related to a cell receptor for low-density 
lipoprotein (LDL) has been identified, while that of ALV-B is related to the tumor necrosis 
factor α (TNFα) (36, 157). The process of intracellular uncoating is not completely 
understood, however, subsequent early events are carried out in the context of a 
nucleoprotein complex derived from the capsid (69).  
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Replication begins with reverse transcription, by RT, of the virion RNA into 
complementary DNA (cDNA) using the 3’-end of a tRNA as a primer for the synthesis of 
a negative-sense cDNA transcript. The tRNA is a cellular molecule that is bound to the 
primer binding site (pbs) located just downstream of the 5’ LTR.  The initial short product 
(to the 5’-end of the genome) transfers and primes further cDNA synthesis from the 
nascent 3’-end of the genome by virtue of the identical r regions at the ends of the viral 
RNA genome (102). cDNA synthesis involves the concomitant digestion of the viral RNA 
via RNAse H activity of the RT protein. The products of this hydrolysis serve to prime 
virus-sense cDNA synthesis on the negative sense cDNA transcripts. In its final form, the 
linear dsDNA transcripts derived from the viral genome contain the LTRs composed of 
sequences from the 3’ (U3) and 5’ (U5)-ends of the viral RNA flanking sequence (R) 
found near both ends of the RNA. The process of reverse transcription is characterized by a 
high frequency of recombination due to the transfer of the RT from one template RNA to 
the other (69). The resulting dsDNA is then integrated, in an apparent random fashion, into 
a chromosome of the host cell where it resides as a provirus. This integration reaction is 
mediated by the viral integrase protein (57, 133), whereby the ends of the viral DNA are 
joined to the cellular DNA, involving the removal of two bases from each end of the linear 
viral DNA and the generation of a short duplication of cell sequences at the integration site 
(69). The viral DNA is inserted and cellular DNA repair enzymes complete the integration 
process (19). ALV lacks a nuclear transport function to move the proviral pre-integration 
complex into the intact nucleus, as a result the integration process is only able to occur in 
cells whose nuclear envelope has broken down as a result of the mitotic process, i.e. ALV 
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can only infect dividing cells (81). The integrated provirus in transcribed by cellular RNA 
polymerase II into virion RNA and mRNA species in response to the enhancer/promoter 
sequences of the proviral LTRs. An mRNA comprising the whole genome serves for the 
translation of the gag and pol genes (54). This results in the formation of a polyprotein 
which is later cleaved to yield the structural proteins, protease, RT, and IN, respectively 
(54). A smaller mRNA consisting of the 5’-end of the genome spliced to sequences from 
the 3’-end of the genome and including the env gene and the U3 and R regions, is 
translated into the precursor of the envelope proteins (54). Capsids assemble at the plasma 
membrane and are released from the cell by a budding process (69). Polyprotein processing 
of the internal proteins occurs concomitant with or just subsequent to the maturation of 
virions as described earlier (54).  
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AVIAN LEUKOSIS VIRUS SUBGROUP J 
History of subgroup J 
 As part of a study examining the status of ALV infection among broiler breeder 
flocks in England in 1988, five isolates, designated HPRS-100 to HPRS-104, were 
obtained (105). Studies to elucidate the subtype of these new isolates using virus 
interference assays with RSV pseudotypes corresponding to known ALV subgroups 
revealed that they were unlike previously known ALVs (105). Further analysis employing 
antisera directed at the known ALVs, either singly or in combination, failed to neutralize 
these new isolates (105). Furthermore, host range studies were carried out utilizing chick 
embryos of varying ALV susceptibility phenotypes (105). The results of these assays also 
showed the new isolates to be unlike all previously known subgroups. Similar studies were 
also undertaken in vitro in cells derived from several avian species; interestingly isolate 
HPRS-103 was able to infect both chicken and jungle fowl cell lines, in addition to turkey 
embryo fibroblasts, a characteristic unknown to all current ALV subgroups (112). With 
this data, in comparison to all other known ALV subgroups, HPRS-103 was designated the 
prototype strain of the new subgroup J ALV (105). From the time of its original isolation 
in England to the point it was designated a novel ALV subgroup in 1991, the aggressive 
practices of acquiring superior genetics by the commercial poultry industry resulted in the 
global dissemination of ALV-J in primary breeding stocks, financially devastating the 
industry.  
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The ALV-J genome 
 Upon comparison to the other known and well studied subgroups of ALVs, the 
prototype ALV-J strain, HPRS-103, had an overall structure of typical slowly transforming 
replication-competent ALV viruses: LTR-leader-gag/pol-env-LTR (6). The sequences of 
the ALV-J LTR regions showed more than 90% homology to that of other ALVs (148), 
although the U3 region within HPRS-103 is lacking the enhancer protein (EFII) binding 
sites found in other ALVs. In addition to the conserved ATG start codon that initiates the 
transcription of the large open reading frame (ORF) encoding the Gag protein, the leader 
sequence has two unique ATG codons further upstream (148).  The sequence of the HPRS-
103 gag and pol genes are highly conserved (96 to 97 percent identity) with those of the 
other ALVs, with the exception of a 22 amino acid deletion in the 3’ region of the protein 
due to the incorporation of a premature stop codon (148). This deletion however, is 
unlikely to affect its functions, as this region has been shown to be unnecessary for viral 
replication in vitro (72). Field strains of ALV-J isolated in the United States have been 
shown to have similar structure and very close sequence homology to the HPRS-103 
prototype strain suggesting that the relationships among ALV-Js may be closer than other 
subgroups (12).  
 Unlike the similar LTR sequences shared between ALVs, the env gene of HPRS-
103 is highly diverged from those of other ALV subgroups (7). The SU (gp85) domain of 
HPRS-103 has only about a 40% sequence homology with the corresponding sequences of 
subgroups A to E, as opposed to the 77 to 87% identity commonly found among other 
ALV subgroups (148). The TM (gp37) has about a 65% identity to that of subgroups A to 
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E, in comparison to the 92 to 95% identity among the other ALV subgroups (148). The 
insertion of a 219bp insertion within the TM domain of HPRS-103, termed the redundant 
TM (rTM), showed 97% homology to the corresponding region of other ALVs, indicating 
its ALV origin (6). Between the 3’ end of the env gene and the LTR is a well conserved 
region among retroviruses that is essential for replication. Within this region are the direct 
repeat elements (DR1), which have been shown to have constitutive transport elements 
(CTEs) that facilitate cytoplasmic accumulation of unspliced RNA of unspliced RNA, 
necessary for proper processing of the viral transcripts(132).  
 The occurrence of a new subgroup of ALV led to speculation of its possible 
origins. Original database searches showed a closer relationship between the env gene of 
an endogenous family of avian retroviruses suggesting these endogenous sequences may 
have been the source of the recombination event (15).  Later studies revealed the existence 
of a novel group of endogenous viral sequences within the chicken genome termed, EAV-
HP, these sequences displayed over a 97% homology to that of HPRS-103 env gene (6). 
These EAV-HP elements, also referred to ev/J (11), were present in multiple copies within 
the genomes of all lines of chickens and in the ancestral jungle fowl, but were absent in 
most other avian species studied (137). To this point, all evidence suggests that the 
evolution of the new subgroup J ALV occurred as a result of recombination between an 
unknown exogenous ALV and the EAV-HP env sequences (7). 
 Unlike the sequences of the previously isolated ALV subgroups, HPRS-103 had a 
150 bp region inserted in the 3’ non-coding region downstream of the DR1 region referred 
to as the E element (also called the F2 or XSR) (7). Previously not known to be associated 
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with the ALV genome, the E element was only found in RSVs, either upstream (Schmidt-
Ruppin SR-A strain) or downstream (Prague strain) of the src gene (14). Although the 
actual function of this region and its role, if any, in disease has yet to be elucidated, it does 
have the ability to bind the transcription factor c/EBP and may also act as an enhancer and 
its role in oncogenesis will be investigated and discussed later in the text (76, 125).  
ALV-J’s induction of neoplastic disease 
 The cells targeted during ALV infection all originate from multipotent progenitor 
stem cells which go on to differentiate into lymphoid, erythroid, myeloid, and other cell 
lineages (56). Before the evolution of ALV-J, subgroups A & B were the most 
predominant ALV subgroups, with the characteristic disease induced by these two 
subgroups being lymphoid leukosis (LL), primarily occurring in B cells of the lymphoid 
lineage (148). Based on descriptions of ALV-J-induced disease in experimental studies 
conducted with meat-type or layer-type chickens, subgroup J was found to induce late 
onset, occurring at a median age of 20 weeks, myeloid leukosis (ML) and renal tumors 
targeting mainly those cells of the myeloid lineage (109).  In the majority of the cases 
described lesions were characterized by neoplastic enlargement of the liver and gross 
skeletal myelocytomas affecting the sternum, ribs, and vertebrae (148). The spleen, testes, 
kidney, and thymus also displayed accumulations of immature granulated myelocytes 
forming myeloid tumors (148). Other tumors identified include histiocytic sarcoma, 
haemangiosarcoma, mesothelioma, granulose cell tumors, pancreatic adenocarcinoma, 
fibroma, and an unclassified leukosis (107). In addition to the mortality resulting from 
tumor induction by ALV-J, field reports suggest that broilers generated from infected 
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breeding flocks may suffer from problems of uniformity, feathering, and inadequate 
performance, although these observations have not been proven experimentally (148). The 
ability of ALV-J to infect cells of the myeloid lineage was further substantiated by the 
demonstration of ALV-J to infect blood monocyte cultures from several different chicken 
lines (2). Furthermore, the ability of HPRS-103 to replicate in the medullary region of the 
lymphoid follicles of the bursa of Fabricius was reduced when compared to ALV-A that is 
able to induce LL (148). However, previous studies have shown that HPRS-103 and other 
ALV-J isolates do not transform chicken bone marrow cell cultures in vitro and that the 
tumors induced by these viruses occur after long latent periods (109). These observations 
and the demonstrations of the HPRS-103 genome to not carry any viral oncogenes 
suggested that ALV-J-induced oncogenesis was initiated by the activation of cellular 
oncogenes through the mechanism of insertional mutagenesis (7, 12, 74). To date however, 
the molecular mechanisms surrounding the myeloid tropism or the low bursal tropism have 
yet to be explained.  
 Interestingly, from about 60% of the cases of ML tumors induced by HPRS-103, 
acutely transforming viruses capable of rapid in vitro transformation of cultured bone 
marrow cells were isolated (110). The occurrence of these acutely transforming viruses 
was also noted in field cases, from which virus isolated from  ML tumors was able to 
rapidly induce myeloid leukosis in experimentally infected chickens, suggesting that 
generation of acutely transforming ALVs is a common feature of ALV-J-induced 
neoplastic disease (22, 110). Recently the observation of lesions indicative of 
erythroblastosis have occurred in field samples submitted for diagnosis (149). From these 
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samples, just as with those of ML, acutely transforming viruses were isolated from these 
neoplastic tissues. As explained earlier, it was suggested that this rapid oncogenic potential 
was derived by the transduction of cellular oncogenes through recombination processes.  
 Oncogenesis initiated by ALV-J infection is predominantly found in the form 
myeloid leukosis (ML) (myleocytomatosis) (109), a characteristic thought to be associated 
with its ability to replicate well in blood monocyte cultures but less so in the lymphoid 
follicles of the bursa of Fabricius (2). Unlike acutely transforming leukemia viruses like 
MC29 or MH2 (56), HPRS-103 does not contain any oncogenes and the virus does not 
transform myeloid cells in vitro, as explained earlier (109). However, its ability to 
transform cells of the myeloid lineage are a direct consequence of its proviral integration 
next to the cellular proto-oncogene c-myc, subsequently enhancing and/or promoting the 
transcription of the oncogene via action of its LTR, resulting in the development of 
monoclonal tumors (55, 64). In experimentally infected embryos or 1-day-old chicks the 
development of bursal lymphomas will occur in approximately 50% to 100% of 
lymphoma-susceptible chicks by this method of cellular oncogene upregulation (20, 50).  
Studies by Fung  indicate ALV-induced structural alterations of the c-erbB gene can 
induce the development of erythroblastosis (51). Unlike c-myc, whose enhanced or 
inappropriate expression of the unaltered protein may induce oncogenesis due to the 
actions of proviral LTR, c-erbB induced oncogenesis may be caused by disruptions in the 
coding sequence of the resulting EGF receptor gene (95). The fact that all proviral 
insertions observed in ALV induced erythroblastosis map to a small region in the middle 
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of the EGF receptor gene strongly suggests that specific truncation of the EGF receptor 
gene is required for oncogenesis (118). 
Economic consequences of ALV-J 
To place an exact total on the annual losses attributed to ALV-J at slaughter would 
be a nearly impossible task. However, estimations of these losses incurred by the 
commercial poultry industry as a whole and based on general neoplastic disease referred to 
as leukosis, can be made based on current statistics. These statistics published by the 
USDA (2005), predicted that in 2003 approximately 8.6 billion broilers were grown out in 
the United States. Of that total number, whole bird condemnations due to leukosis 
averaged 0.005% per company. So with efforts to control ALV-J by eradication in place at 
the breeder level (to be discussed in further detail later in the text), the industry still lost 
over $200K when the average price per pound of chicken meat was 30.5 cents (139). These 
are only losses incurred at slaughter; the losses due to poor growth and reduced feed 
conversion would significantly out number losses from condemned carcasses. Prior to the 
implementation of strict eradication policies for infected birds and the development of 
accurate diagnostics, the mortality in breeder females could have reached an overall high 
of 6% per month or higher at its peak, while mortality levels in males caused significant 
infertility issues (156).  Tumors of various kinds would have been found in up to 60-70% 
of dead birds in severely infected flocks, with myelocytomas being the most common type 
of tumor (156). In the late 1990’s it was not unusual for commercial broilers, hatched from 
breeder flocks with high virus shedding rates, to experience uniformity problems, paleness, 
abnormal feathering, inadequate performance and high late overall mortality (>5 wk of 
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age), usually associated with respiratory disease complications (156). Currently, the major 
economic impacts associated with ALV-J infection are distributed worldwide, but have 
been restricted to the primary breeder industry. A study conducted by Palya et al. in 
Hungary examined the effects of an ALV-J infection in a meat-type breeder flock; in total 
24.3% of the animals died due to the direct or indirect consequence of the ALV infection 
and egg production fell behind the expected level by about 32% (101). As a consequence 
of the continuous high mortality rate and the suboptimal level of egg production, the flocks 
were slaughtered 2 months before the end of the normal production period (101). 
Worldwide, ALV-J associated loss rates, reported in breeders vary from 3-20% (5).  
Within the United States the few primary breeder companies who still remain have 
substantially increased their detection and eradication efforts and disease in this country is 
not as severe as in other parts of the world. But, efforts to control ALV-J by eradication 
have placed harsh selection pressures on valuable genetic stock resulting in the loss of 
pedigree birds. In addition to the eradication costs, the cost of continually monitoring 
breeder flocks for ALV-J infection can be extreme.  
ALV-J diagnostics 
 Exogenous ALV and in particular ALV-J infections in a flock can be provisionally 
diagnosed by pathological identification of characteristic tumors and confirmed by various 
virological methods. The majority of ALV diagnostics in use today can be placed into two 
distinct categories: 1) those based on the detection of specific proteins or glycoproteins 
encoded by one or more of the three major genes of ALV, namely gag, pol, and env, and 2) 
the detection of specific sequences of proviral DNA or viral RNA by polymerase chain 
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reaction (PCR) and/or reverse transcriptase (RT)-PCR (41). The detection of both 
endogenous and exogenous ALVs can be further classified into biological, molecular, and 
serological assays (45, 108). The gold standard used today by the majority of the 
commercial poultry industry can be classified as a biological assay, whereby it employs 
cell culture to isolate and grow ALV before detection of p27 protein, the most abundant 
structural polypeptide produced by all ALVs. This time consuming step is necessary in a 
biological assay because most ALVs produce no cytopathic effects (CPE) in culture, 
making detection of p27 the basis of several diagnostic tests. Indirect biological assays 
such as complement fixation (CF) for avian leukosis (COFAL) (127), enzyme-linked 
immunosorbent assay (ELISA) (31, 45), phenotypic mixing (PM) (97), resistance inducing 
factor (RIF) (124), nonproducer cell activation (NP) (121), and flow cytometry (4) tests 
have been developed and used for detection of ALVs.  Phenotypes of CEFs used for 
detection of ALV are listed in Table 2. Common diagnostic practices within the primary 
breeder industry aim to only detect all exogenous subgroups of ALV, making the C/E cell 
lines the most desirable. Although, other cell types such as those resistant to subgroup A 
(C/A) (32) and resistant to ALV-J (C/J) can also be used to confirm the subgroup of the 
isolated ALV (68). The differentiation of exogenous and endogenous ALV can be 
facilitated by culture in both cells resistant to endogenous (C/E) virus and cells susceptible 
to exogenous (C/O) virus. If the sample is positive for p27 in C/O cells but not in C/E 
cells, the sample is assumed to be positive for endogenous ALV, whereas positive results 
in both cell lines indicate an exogenous ALV. Most commonly, samples used for detection 
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of ALV include blood, plasma, buffy coat, meconium, cloacal/vaginal swabs, egg 
albumen, embryos, and tumors (33, 43, 45, 140). 
Table 2. Phenotype of chicken embryo fibroblasts (CEFs) used for isolation and identification of most 
common ALVs from chickens. A,B(31), C(32) , D(68). 
Designation 
of CEF 
phenotype 
Susceptible to 
ALV of 
subgroup 
Resistant 
to ALV of 
subgroup 
Used for isolation of 
identification of ALV 
subgroup 
Example of cell line and 
referece 
C/O A, B, C, D, E, J None All subgroups of ALV 15B1; Crittenden et al., 1987 
C/E A, B, C, D, J E Exogenous ALVs only Line 0; Crittenden et al., 1987 
C/AE B, C, D, J A, E Rule out subgroups A and E ALV 
Alv 6; Crittenden & 
Salter, 1992 
C/EJ A, B, C, D E, J Rule out subgroups E and J ALV DF-1/J; Hunt et al., 1999 
 
 Assays which test directly for ALV infection have largely relied on the detection of 
gs antigen (p27), a protein encoded by the gag gene of ALVs. Assays which rely on the 
detection of antibody can often be misleading due to the varying types and phases of ALV 
infection (148). For example, birds congenitally exposed or those birds infected by hatch 
mates may not develop an immune reaction, and therefore develop a persistent viremia and 
no antibodies to ALV (148). Using direct ELISA or the CF test, ALV p27 can be detected 
in samples of albumen, meconium, cloacal/vaginal swabs, or feather pulp (45, 108). 
Utilizing monoclonal antibodies against ALV p27 (35), the most common direct method of 
ALV detection is acELISA for p27, and commercially available kits have been developed. 
Monoclonal antibodies also exist for the detection of envelope glycoproteins (gp85) of 
AVL-J (40). Radioimmunoassays can also be used for the detection of p27 and were 
consistently found to be more sensitive than CF in detecting exogenous and endogenous 
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ALV (41). In sections of tumor of other tissue immunocytochemical staining procedures 
such as immunofluorescence, immunoperoxidase anti-peroxidase, or protein A-gold can 
also be used for detection of p27 associated with ALV virions (53).  
 Biological systems used to detect ALV, such as susceptible ALV-free chickens, 
chicken embryos, and CEFs are among the most reliable and most commonly used 
methods for isolation and identification of ALV. As described above, this ALV diagnostic 
technique allows the detection of infectious virus, antigen, and/or antibody and has been 
instrumental in control and eradication programs within the industry. 
 Today the most common method to isolate and identify ALV first involves samples 
to be cultured in CEFs. Since most ALVs produce no CPE, indirect biologic assays such as 
COFAL, acELISA, PM, RIF, and NP cell activation tests are used to detect the presence of 
ALVs. The acELISA has become the tool of choice for those who require a sensitive, 
practical, and economical assay for ALV detection. This method is carried out in two 
distinct parts; first the virus is propagated in CEFs (most often C/E) for approximately 
seven days, this is followed by the assaying the cell lysates, via acELISA, for ALV p27 gs 
antigen. 
 The latest and most rapidly advancing form of diagnosing ALV infection involves 
molecular technology. The complete ALV genome has been elucidated and this 
information has spawned the development of an array of primers and probes designed to 
detect many aspects of the ALVs (6, 7, 25). Unlike the methods relying on the biological 
amplification of ALV, this technology allows the rapid detection of ALV during early 
stages of infection (146). The use of molecular-based diagnostic techniques for the 
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detection ALV have been investigated (52, 73, 135, 136). PCR methods have been 
previously developed for the amplification of ALV-J from many different sample types 
including serum, whole blood, meconium, and feather tips (6, 52, 73, 135, 136). Primers 
developed for these assays have been targeted towards the sequences of the env gene or 
LTR regions of the ALV genome (135, 136). Additional regions of amplification for PCR 
include the 3’ non-coding region, the E element, the H5-H7 located in the 3’ region of the 
polymerase gene, and the 5’ region of the gp85 portion of the env gene (135, 136). While 
the amplification of these regions of the ALV genome have proven sensitive and specific 
for the detection of ALV, the continual evolutionary pressure on these portions of the ALV 
genetic sequence create an ongoing trend of mutation (131, 148, 150).   
The development of real-time monitoring systems for PCR amplification have been widely 
accepted and adapted for the detection and quantification of selected genes (98). This 
method of ALV detection gives superior sensitivity by the use of Taqman primer/probe 
chemistry, in addition, the length of the amplified transcripts are shorter and can be 
directed at smaller regions conserved within the ALV genome, affording greater 
specificity.  
Control and eradication 
The control of ALV-J presented a significantly challenging problem for the 
commercial poultry industry following its isolation in the late 1980s.  In an effort to 
control this new subgroup of ALV,  methods adopted by the industry have been primarily 
focused on it’s eventual eradication (42, 96, 99, 111, 138). This goal however, has been an 
elusive one. The environment, population densities, and rearing practices of the modern-
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day commercial poultry facility make isolating and eliminating infected birds in a timely 
manner very difficult. And unlike the other ALV subgroups, the extreme proficiency by 
which ALV-J is able to infect both horizontally and vertically, only compounds this 
problem, requiring eradication programs to be applied more rigorously (153, 154). 
Removal of ALV positive birds identified by the current industry ‘gold standard,’ cell 
culture coupled with acELISA, can at best occur approximately 8 days after the sample 
was collected. This period allows ample time for the horizontal transmission of virus to 
littermates and continued vertical transmission by breeders, inciting a chain of infection 
that is nearly impossible to break without detrimental consequences to breeding stock. The 
industry has taken steps to counter ALV-J’s infectious proficiency; large whole-house 
breeder facilities have evolved into methods employing small pen rearing, limiting 
exposure to other birds within the same house (154).  
Biosecurity is always a first defense against any exogenously spread disease and 
these measures should be applied to any scheme aiming at controlling and eradicating 
ALVs. The notion of conferring protection through vaccination has been investigated, but 
as with most, if not all retroviruses, their widespread antigenic diversity and lack of 
knowledge on immunogenic properties of different viral antigens, make development of an 
effective vaccine a challenging task (148). Currently, a shift in methods of surveying for 
and diagnosing exogenous ALV is taking place. The acELISA and anti-ALV antibody 
surveillance tests have been proven to not be completely reliable and less sensitive than 
diagnostic techniques currently available (1, 52, 149). However, molecular diagnostic 
techniques offer extreme sensitivity and specificity, provide rapid results, and can be 
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preformed in a high-throughput manner at a cost equivalent to or less than the current ‘gold 
standard’ method, as presented in the following manuscript.  
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DEVELOPMENT OF A HIGH-THROUGHPUT QUANTITATIVE REAL-TIME 
RT-PCR ASSAY FOR RAPID DETECTION OF EXOGENOUS AVIAN LEUKOSIS 
VIRUS 
Overview 
Avian leukosis viruses (ALVs) have caused significant economic losses worldwide 
in meat-type chickens by diminishing feed conversion, inciting neoplastic disease resulting 
in condemnations at slaughter, and increasing mortality. Based on differences in their 
envelope glycoproteins, virus-serum neutralization tests, virus interference, and host range 
these viruses in chickens are classified into six subgroups. The most recently discovered 
ALV, subgroup J, was isolated from meat-type chickens associated with myleocytomatosis 
in England in the late 1980s. The host range of ALV-J encompasses jungle fowl, turkeys, 
and meat-type birds at all breeding generations including commercial broiler flocks. 
Beginning in the early 1990s the commercial broiler industry was confronted with this new 
subgroup of ALV, when it began causing serious mortality and production problems 
worldwide. Eradication programs based upon virus isolation and identification were 
initiated by primary breeder companies in order to produce virus free breeding stock. A 
multitude of primary breeders have had meager success, in a large part due to the 
techniques employed for exogenous ALV detection. In order to increase sensitivity and 
provide a rapid analysis of samples, a qrRT-PCR assay was designed and developed by 
this laboratory to amplify a  specific sequence conserved among the exogenous ALV 
subgroups A, B, C, D, and J while excluding amplification of endogenous viruses (ev) or 
ev sequences within the chicken genome. The sensitivity of the resulting one-tube 
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hydrolysis fluorogenic probe based reaction developed in this study was calculated to 
consistently amplify less than 20 copies of in vitro transcribed RNA. In addition, we 
analyzed 275 buffy coat samples drawn from pedigree broiler lines of one primary breeder 
company within the United States. The results of both virus isolation and qrRT-PCR from 
these samples were compared and the data correlated highly. The increased detection 
yielded by the qrRT-PCR assay was approximately 160% greater than VI. In addition, the 
lower range of detection of our qrRT-PCR assay was considerably greater than that 
detected following virus isolation. This contemporary method of exogenous ALV detection 
allows for the real-time quantification of ALV RNA copy numbers, is extremely sensitive, 
specific, cost effective, and easily performed in a high throughput manner, resulting in an 
assay able to provide a practical and efficient tool for commercial breeder operations to 
monitor and eventually eradicate ALV within their primary breeding stock. 
Introduction 
The avian leukosis viruses (ALVs) are grouped into the Alpharetrovirus genus of 
the family Retroviridae (120). These viruses in chickens are classified into six subgroups: 
A, B, C, D, E, and most recently J (106). Their distinctions arise from differences in 
envelope glycoproteins, virus-serum neutralization tests, virus interference, and host range 
(71). ALVs are known to cause a variety of neoplasms including erythroid, lymphoid, and 
myeloid leukoses (109, 110, 149). The ubiquitous endogenous ALVs of subgroup E have 
low pathogenicity and are transmitted vertically through inherited host genes, unlike the 
transmission of exogenous ALVs that occurs both vertically and horizontally (30). Of these 
exogenous subgroups, A and B are the most common ALVs, while subgroups C and D 
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have been rarely reported in commercial poultry due in large part to the eradication efforts 
of the commercial poultry industry (21, 108). The pluripotential neoplasms of ALVs cause 
severe economic losses due to condemnations at slaughter, loss of pedigree birds, and 
tumor mortality. The most recently discovered ALV, subgroup J, was isolated from meat-
type chickens associated with myleocytomatosis in England in the late 1980s (105). ALV-J 
was predicted to be a recombinant of exogenous ALVs and the EAV family of endogenous 
avian retroviruses (6). The host range of ALV-J encompasses jungle fowl, turkeys, and 
meat-type birds at all breeding generations, including commercial broiler flocks (44, 109). 
The commercial broiler industry was first confronted with this new subgroup of ALV in 
the early 1990s, when its impact began causing serious production problems and mortality 
on a global scale (106, 141).  
 To date, the ‘gold standard’ assay employed by the commercial poultry industry to 
determine ALV infection involves the detection of the viral group specific antigen (gs) p27 
by antigen-capture (ac) enzyme-linked immunosorbent assay (ELISA) (138). This 
technique however is not specific and when used exclusively it will detect p27 encoded by 
ev sequences, in turn applying undesirable, and costly selection pressure on pedigree stock 
(156). Since p27 is shared by both endogenous and exogenous ALVs, exclusive use of 
ELISAs cannot be used to identify and differentiate ALVs. To prevent the detection of ev 
p27 and increase specificity, samples must first be inoculated onto chicken embryo 
fibroblasts (CEFs) prior to acELISA (45). The most commonly used CEFs to isolate and 
detect AVLs by the commercial poultry industry include C/E, which are susceptible to 
infection only by exogenous ALV subgroups. Cells susceptible to infection from all 
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exogenous and endogenous ALV subgroups, C/O CEFs, can also be used for ALV 
isolation (31, 41, 45). This technique of virus isolation (VI) and antigen detection is time 
consuming, requiring 8-10 days to complete, it is also laborious, and expensive.  
 Methods to control ALV have been primarily focused on it’s eventual eradication 
(42, 96, 99, 111, 138). This goal however has been an elusive one for the commercial 
poultry industry. The environment, population densities, and rearing practices of the 
modern-day commercial poultry facility make isolating and eliminating infected birds in a 
timely manner very difficult. The proficiency of ALV-J to infect both horizontally and 
vertically only compounds this problem (153, 154).  Removal of ALV positive birds 
identified by cell culture coupled with acELISA can at best occur approximately 8 days 
after the sample was collected. This period allows ample time for the horizontal 
transmission of virus to littermates and continued vertical transmission by breeders, 
inciting a chain of infection that is nearly impossible to break without detrimental 
consequences to breeding stock.  
 The use of molecular-based diagnostic techniques for the detection ALV has been 
investigated (52, 73, 135, 136). Polymerase chain reaction (PCR) methods have been 
previously developed for the amplification of ALV-J from many different sample types 
including serum, whole blood, meconium, and feather tips (6, 52, 73, 135, 136). Primers 
developed for these assays have been targeted towards the sequences of the envelope (env) 
or long terminal repeat (LTR) regions of the ALV genome (135, 136).   
 Additional regions of amplification for PCR include the 3’ non-coding region, the 
E element, the H5-H7 primer set spanning the 3’ integrase region of the pol gene to the 5’ 
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region of the gp85 portion of the env gene (135, 136). While the amplification of these 
regions of the ALV genome have proven sensitive and specific for the detection of ALV, 
the continual evolutionary pressure on these portions of the ALV genetic sequence create 
an ongoing trend of mutation (131, 148, 150).   
The development of real-time monitoring systems for PCR amplification have been 
widely accepted and adapted for the detection and quantification of selected genes (98). 
The ability of this new quantitative real-time reverse transcriptase PCR (qrRT-PCR) 
technology to rapidly analyze and provide results is only limited by the time needed to 
extract the RNA/DNA template from individual samples. The high-throughput feasibility 
of this assay was retained by the use of magnetic bead technology, first described by 
Guesdon et al. (60). Adaptation of this magnetic bead technology to isolate both viral RNA 
and proviral DNA in a 96-well plate format was employed to acquire the template for this 
qrRT-PCR assay. The objective of this study was to develop a new high-throughput one-
tube qrRT-PCR assay using a hydrolysis fluorogenic probe for the specific detection and 
quantification of only exogenous ALVs to rapidly identify and remove infected birds, 
limiting horizontal and vertical transmission. The application of this assay in the detection 
of exogenous ALV subgroups from clinical samples such as buffy coat (BC) and plasma is 
discussed; also a comparison of this assay to VI and acELISA is made.  
Materials and methods 
     A. Diagnostic samples 
BC and plasma samples were obtained from a U.S. primary breeder company. 
Diagnostic samples were shipped on dry-ice in 96-well microtiter plates, with each plate 
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corresponding to a random sample of 7 week-old pedigree birds within three different 
brooder houses (A,B, & C) on the same complex.    
     B. Nucleic acid extraction 
 Viral RNA was extracted from 50 µl plasma samples with the use of RNA-binding 
magnetic particles supplied by the MagMAXTM Viral RNA Isolation Kit developed by 
Ambion®, Inc. (Austin, Texas, USA). The manufacturer’s protocol for cell free sample was 
followed. In an effort to simulate authentic high throughput evaluation of clinical samples 
in a 96-well plate format, the robotic extraction of viral RNA from plasma using the 
MagMAXTM components was carried out by Ambion®, Inc. (Austin, Texas). 
 Total nucleic acid from BC samples was also extracted with the use of the 
MagMAXTM kit (Ambion®, Inc. Austin, Texas). The manufacturers’ protocol was 
optimized. Briefly, 10µl of BC samples were transferred into new 96-well plate, 60µl of 
nuclease free water was added and the plate was then shaken with a DPC MicroMix® 5, 
(form 5, amplitude 15) for 1 min. Fifty microliters of this suspension was then used for 
isolation of total nucleic acid following the normal MagMAXTM Viral RNA Isolation Kit 
protocol. 
     C. Development of a one-tube real-time quantitative RT-PCR 
 Sequence data and phylogenetic analysis by Garcia et al. (52) has demonstrated 
that the long terminal repeat (LTR) U3 region of the ALV genome is closely related among 
exogenous subgroups and more distant from U3 LTR regions of endogenous viruses. 
Using this preliminary data and additional exogenous ALV sequences obtained by this 
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laboratory, the DNASTAR group of programs was used to design a set of primers and 
probe within this region of the exogenous ALV genome (DNASTAR, Inc., USA). 
 Oligonucleotide primers used in the study were a forward primer (XALV-F) and a 
reverse primer (XALV-R) designed to amplify a conserved 112 bp region within the LTR 
of the ALV genome. This pair of primers was developed to specifically amplify all 
exogenous subgroups of ALV and did not amplify sequences of the endogenous subgroup 
E ALVs. The specificity of these primers was tested for all known strains of exogenous 
ALVs, subgroups A, B, C, D, and J, and on twelve samples derived from inbred and 
congenic chicken lines with known endogenous gene loci. Additionally, a BLAST search 
was carried out against the GeneBank database and no sequences of known endogenous 
virus identified. A fluorogenic probe labeled with 56-FAM and 3BHQ-1 was also 
developed that would bind within the location of the primers XALV-F and XALV-R 
(Integrated DNA Technologies, Inc., Coralville, Iowa). 
 Complementary DNA (cDNA) was amplified using the primers RUGZ-F and 
RUGZ-R from a recent ALV-J field isolate (156). Following RT-PCR, the amplicon was 
ligated to the pCR®-XL-TOPO® cloning vector (Invitrogen, Carlsbad, California, USA). 
The recombinant plasmid vector was transformed into the chemically competent One 
Shot® TOP10 strain of Escherichia coli (Invitrogen, Carlsbad, California, USA). 
Transformed colonies were selected following an 18 h incubation at 37oC on Luria Broth 
(LB) plates containing 50 µg/ml Ampicillin. The plasmid was then purified from these 
cultures (QIAprep® Spin Miniprep Kit, Qiagen, Valencia, California, USA) an the desired 
insert and it’s direction was visualized by the presence of a 649 bp product on 2% agarose 
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gel following PCR amplification using the primers XALV-F and M13 Forward Primer 
(Invitrogen, Carlsbad, California, USA). Purified plasmid DNA containing the desired 
insert in the proper orientation was linearized with Hind III (Fisher Scientific, Pittsburgh, 
Pennsylvania, USA) for 3 h at 37oC an in vitro transcription was performed using a 
commercial kit (T7 RiboMAXTM Express Large Scale RNA Production Systems, Promega, 
Madison, Wisconsin, USA). Following in vitro transcription, RNase-free DNase was 
added and incubated at 37oC for 30 min. RNA transcripts were then precipitated via 
phenol/chloroform, washed and dried. Briefly, 750µl of Trizol LS was added to the in vitro 
transcribed RNA product, it was then vortexed and incubated at room temperature for 5 
min. Two-hundred microliters of CHCl3 was then added to a 1.5 ml Eppendorf tube, 
vortexed, and incubated for 10 min. This suspension was then centrifuged at 12,000 rpm at 
4oC for 10 min. Following the centrifugation the upper aqueous phase was transferred to a 
new 1.5 ml Eppendorf tube, 500µl of isopropyl alcohol was added to the sample, vortexed, 
and incubated at room temperature for 10 min. This was followed by an additional spin at 
4oC at 12,000 rpm for 10 min, precipitating the RNA into a pellet. This pellet was finally 
washed once with approximately 1 ml 75% ethanol and repelleted by centrifugation. The 
resultant pellet was then redissolved in 50 µl of RNase free molecular grade H2O and RNA 
concentration was determined using a biophotometer at A260 nm (Eppendorf, Hamburg, 
Germany). The RNA was divided into single use aliquots containing 1x106 copied per 
microliter and stored at -80oC. 
 qrRT-PCR was performed on control and viral RNA in ten-fold serial dilutions to 
determine amplification efficiencies. Standard curves for the respective RNAs were 
38 
 
calculated by plotting their threshold cycle (CT) values versus their dilution factors. 
Control RNA was diluted from approximately 106 to 100 copies per microliter of sample 
input into the qrRT-PCR assay. A standard curve was then derived for extrapolation of 
viral RNA copy numbers from individual samples. The slopes of these standard curves 
were then compared to each other. Efficiencies were defined as equal if the difference of 
the slopes was smaller than 0.1 (61).  
 The total volume of the qrRT-PCR reaction was 25 µl and included 7 µl of 
template solution, the XALV-F and XALV-R primers at a concentration of 200 nmol and 
the hydrolysis fluorogenic probe at a concentration of 100 nmol. The remaining 
components used in this reaction were provided by the QuantitectTM Probe RT-PCR Kit 
(Qiagen, Valencia, California, USA) and formulated according to the manufacturer’s 
instructions.  
The protocol for the qrRT-PCR assay consisted of 50oC for 30 min, 95oC for 13.5 
min, and 45 identical cycles of 95oC for 10 s, 52.5oC for 30 s, and 76oC for 30 s. The 
reverse transcription and cDNA amplification were carried out in a single tube in a Biorad 
iCyclerTM thermocycler coupled with the MyiQTM Single-Color Real-Time PCR Detection 
System (Biorad Laboratories, Hercules, California, USA). This system adds a 1.5 min 
cycle directly following the first cycle to reach 95oC in order to read initial fluorescence 
and calculate the needed adjustments to compensate for pipetting errors. The software that 
accompanies the detection system displays amplification data in real-time and derives 
individual CT values according to a calculated base line value on completion of the 
reaction.   
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     D. acELISA 
  In addition to qrRT-PCR, BC and plasma samples were inoculated onto cell 
culture to determine the presence of ALV-J by detection of p27 antigen. Briefly, 100µl of 
sample was simultaneously inoculated onto 48-well tissue culture plates containing 
1.5x105 DF-1 cells per well in 4% growth medium, containing 3.76 g Leibovitz L-15 
Medium, McCoy’s 5A Medium Mix, 1.1 g NaHCO3, 20 ml (4%) fetal bovine serum 
(FBS),1 mg amphotericin B, 12.5 mg gentamycin, 1 mg DEAE dextran, 2000 units of 
heparin, and brought to a volume of 500 ml. Following 24 hr incubation the media was 
removed and replaced with maintenance media (1% FBS growth media without DEAE 
dextran and heparin) and incubated for an additional 7 days.  Plates were then processed 
for p27 antigen by the addition of 50 µl 5% Tween 80 to each well followed by two freeze-
thaw cycles. One hundred-microliter aliquots of cell lysates were collected from each well 
and transferred to 96-well plates for acELISA detection. ALV acELISA assay protocol and 
readings were performed according to the manufacture’s recommendations (IDEXX 
Laboratories, Westbrook, ME) except a sample to positive ratio (S/P) cutoff value of 0.1, 
less stringent than the manufacture’s recommendation of 0.2, was used to call positives. 
S/P ratios were calculated by subtracting the negative control mean absorbance value at 
650 nm, A(650), from the sample mean and dividing this value by the value obtained from 
subtracting the negative control mean at A(650) from positive control mean at A(650).  
{[(sample mean – negative control mean)/(positive control mean – negative control mean)] 
= S/P} 
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     E. Calculations 
  Simple қ coefficients were calculated using the formula: kappa = (observed 
agreement – chance agreement) / (total observed – chance agreement). қ values were 
interpreted as follows: <0 – no agreement, 1.0 to 0.19 – poor agreement, 0.20 to 0.39 – fair 
agreement, 0.40 to 0.59 – moderate agreement, 0.60 to 0.79 – substantial agreement, 0.80 
to 1.00 – almost perfect agreement (77). Trend lines were calculated using the polynomial 
trend line feature of Microsoft® Excel with an order of two. 
Results 
     A. qrRT-PCR 
 The specificity of the resulting primers and probe was tested against purified DNA 
from cells previously infected with ALVs A, B, C, D, and J, DNA from different chicken 
lines carrying endogenous loci and DNA from RAV-0 infected cells. Also a BLAST 
search was performed on the chicken genome, no results were found to correlate with ev 
sequences. A nearly 100% agreement was found when comparing sequence identity of the 
avian leukosis virus genome (Genebank accession number NC_001408)  and the primers 
and probe set referred to earlier for exogenous ALV detection (13). The real-time PCR 
analysis of these samples only amplified the exogenous proviral DNA of ALVs A, B, C, D, 
and J. No amplification products were observed for ev RAV-0 or any of the genomic DNA 
from the chicken lines tested (data not shown). 
     B. Quantitative real-time RT-PCR 
 Quantitative real-time RT-PCR of control RNA was used to generate amplification 
plots and standard curves for extrapolation of proviral DNA and viral RNA copy numbers 
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(Figure 2 & Figure 3). The sensitivity of the qrRT-PCR was determined by amplification 
of serial 10-fold dilutions of control RNA. Sensitvity yielded by the qrRT-PCR assay was 
determined to be approximately 20 copies of target sequence.      
 
 
 
Figure 2. Standard curve depicting the threshold cycles (CT) values vs. the starting quantities of 
standard RNA dilutions of control RNA. The amounts of control RNA added were log dilutions from 
approximately 3.66 ng/µl to 3.66 ag/µl. The regression line is linear and CT values are highly 
correlated with starting RNA quantity. Exogenous ALV copy numbers were calculated based on the 
line equation derived by the standard curve. 
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Figure 3.  Amplification plot of control RNA dilutions containing (left to right) 7x108, 7x107, 7x106, 
7x105, 7x104, 7x103, and 7x102 copy numbers, respectively for use in deriving a standard curve. 
 
C. Detection of exogenous ALV from buffy coat samples 
 Virus isolation, qrRT-PCR of cell culture lysates (CC L), and qrRT-PCR of 275 BC 
samples from three grandparent flocks are shown in Table 3. A total of 24, 26, and 16 BC 
samples were positive for exogenous ALV via VI in DF-1 cells, whereas qrRT-PCR of the 
same lysates used in the acELISA, following VI, detected 29, 40, and 14 positive samples. 
qrRT-PCR of extracted nucleic acid from the BC samples of houses A, B, and C yielded 
50, 65, and 57 positives, respectively (Table 3). 
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Table 3. Detection of exogenous ALV in buffy coat samples by VI and qrRT-PCR. ATP = true positive, 
number of samples VI+/qrRT-PCR+; TH = trure negative, number of samples VI-/qrRT-PCR-; FN = 
false negative, number of samples VI+/ qrRT-PCR-; FP = false positive, number of samples VI-/qrRT-
PCR+;     SE = % sensitivity, TP/(TP + FN) x 100; SP = % specificity, (TN/(FP + TN) x 100;  қ = kappa 
coefficients, measure of agreement between virus isolation and qrRT-PCR. 
 
              Positive Samples / Avg. value         
Comparison of assaysA 
Flock 
No. 
samples VI 
VI 
CCS 
qrRT-
PCR TP TN FN FP SE SP қ 
A 92 24 29 50 20 37 4 31 83.3 54.4 0.28 
B 91 26 40 65 24 24 2 41 92.3 36.9 0.20 
C 92 16 14 57 16 35 0 41 100.0 46.1 0.23 
 
 
 Virus isolation was compared to the results of qrRT-PCR (Table 3). True positive 
(TP) BC samples (VI+/qrRT-PCR+) detected in houses A,B, and C were 20, 24, 16, 
respectively. Twenty-four, 35, and 37 true negative (TN) samples (VI-/qrRT-PCR-) of BC 
were found in houses A, B, and C, respectively. False negative (FN) BC samples (VI+/ 
qrRT-PCR-) ranged from 0-5 per house. Notably, in the BC samples obtained from houses 
B and C there were 41 false positives (FP) samples (VI-/ qrRT-PCR+) (Table 3). The 
sensitivity (SE) of the qrRT-PCR assay developed detected copies of exogenous ALV 
nucleic acid ranging from 78.3% to 100% when compared to VI among the three houses, 
whereas the specificity (SP) ranged from 30.5% to 54.0% (Table 3).  
 Table 4 illustrates that increased S/P ratios, those samples found by VI to contain 
higher concentrations of p27 (higher virus titers), correlate to decreased CT values in qrRT-
PCR and in turn higher copy numbers of viral nucleic acid. In an S/P range of 0.000 to 
0.099 the average value calculated among samples of all three houses was 0.037 in 208 VI 
negative samples, whereas qrRT-PCR amplified target sequence in 113 samples with an 
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average CT of 38.52. In an S/P range of 0.100 to 0.199 the average value calculated was 
0.133 in 11 VI positive samples and qrRT-PCR amplified target sequence in 9 samples 
with an average CT of 36.58. Between the S/P values of 0.200 to 0.499 the average value 
calculated was 0.292 in 36 VI positive samples, while qrRT-PCR amplified target 
sequence in 32 of those samples with an average CT of 34.92. Spanning the S/P range of 
0.500 to 0.999, VI detected 9 positive samples with an average value of 0.718 and these 
samples were also found to be all positive by qrRT-PCR, with an average CT of 34.42. 
There were 10 samples found to have an S/P ratio of greater the 1.000 following VI, those 
same samples were also found positive by qrRT-PCR and the average CT was calculated as 
31.37. The statistical analysis of this data was expressed by a simple қ coefficient. A 
simple қ coefficient of 1 indicates a perfect agreement between assays, whereas a қ 
coefficient of 0 indicates no agreement between assays. 
 
 
Table 4. Sensitivity comparison of exogenous ALV detection by VI and qrRT-PCR. AAverage value for 
VI stated as: S/P = ([Sample absorbance] - [average negative control absorbance])/positive control 
absorbance; VI CCS & qrRTPCR = CT (threshold cycle). BS/P cutoff. CqrRT-PCR value = CT 
(threshold cycle). 
 
      Average combined values of houses A,B,&C 
    No. of samples / value  
S/P rangesA   VI    qrRT-PCRC 
0.000-0.999  208 / 0.037  113 / 38.52 
0.100B-0.199  11 / .133  9 / 36.508 
0.200-0.499  36 / .292  32 / 34.92 
0.500-0.999  9 / .718  9 / 34.42 
> 1.000   10 / 1.38   10 / 31.37 
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Charted in Figure 4 are the BC samples found positive in VI and their 
corresponding S/P ratios in addition the CT values obtained directly from the extracted 
nucleic acid of the same BC samples and from the CCL following VI. As depicted by the 
trend lines of the qrRT-PCR assays the CT values, corresponding to viral RNA copy 
numbers, highly correlate with the increased S/P ratios. Accordingly the CT values of the 
CCL contained an average of 107.4 copies more than copies extracted directly from BC 
samples.  
15
20
25
30
35
40
45
1 6 11 16 21 26 31 36 41 46 51 56 61 66
Positive VIs
C
T
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
S/
P
qrRT-PCR (CT)
CCS (CT)
VI Positives (S/P)
Trendline of BC qrRT-PCR
Trendline of CCS qrRT-PCR
 
Figure 4. Trend lines of qrRT-PCR (quantitative real-time RT-PCR) CT (threshold cycles) values of 
BC (buffy coat) and CCL (cell culture lysate) samples versus the S/P (sample/positive) ratios following 
VI (virus isolation).  
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Discussion 
 The rapid identification and elimination of ALV positive birds is essential for the 
eradication of this virus from commercial primary breeding stock, and the continued 
financial success of the breeder company. The severe economic losses brought on by the 
rapid global dissemination of ALV-J within the primary breeder industry which occurred 
following its initial identification and isolation in the late 1980s clearly illustrate the need 
for the continual monitoring and eventual eradication of all exogenous ALV subgroups. 
Many obstacles will hinder if not prevent the elusive goal of eradication from ever being 
realized. The most important of these obstacles is the predominantly used diagnostic 
technique of VI, still considered the industry’s ‘gold standard.’ This method requires 
within the sample infectious virus and in most instances the absence of inhibiting 
antibodies, two criteria which cannot be easily controlled. With these criteria met, and 
assuming no bacterial or fungal contamination of the cell culture has occurred, the 
elimination of positive birds can happen, at the earliest, seven days post acquirement of the 
sample. The dissemination of ALV-J infection in exposed birds is inevitable following this 
prolonged method of diagnosis, in turn inciting a course of infection that is near impossible 
to break.  Secondly, the established dogma of ALV infection is based on the this method of 
diagnosis, which this study and others have shown to be less sensitive than PCR based 
technologies (52, 135).  This dogma is founded on four classifications of ALV infection: 
the presence (+) or absence (-) of viremia (V), serum antibodies (A), and viral shedding (S) 
(148). These infection profiles can be further described or categorized as consistently 
positive, transiently positive, intermittently positive, and negative (153). Applying VI as a 
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diagnostic technique, Witter et al. (153) has provided detailed studies of bird responses to 
ALV-J infection. Consequently, VI responses of intermittently and transiently positive 
birds were characterized as inconsistent from weeks 12-62 post hatch, which may be 
explained by the presence of virus neutralizing antibodies present among these categories 
of birds between weeks 20 and 40 of age (153).  The existence of the retrovirus infection 
classification described as V-A+S+ is evidence to the reduced sensitivity of VI when 
compared to PCR-based technologies.  
As previously established by Garcia et al. (52) and further substantiated in this 
study, the 3’ LTR region of the ALV genome is  highly conserved among exogenous ALV 
strains, and is therefore considered a superior target of amplification for development of an 
ALV diagnostic for commercial applications. The primers and probe designed in this assay 
provide extreme sensitivity, detecting in most cases less than 10 virus particles (data not 
shown). In addition, the specificity of theses primers and probe was further shown by the 
absence of amplification when run against the DNA of ubiquitous ev loci. The 
amplification of all exogenous ALV subgroups, while excluding ev loci, is advantageous 
because it is the exogenous subgroups which cause detrimental effects within commercial 
poultry production, therefore making these subgroups targets of eradication.    
The sensitivity obtained from the qrRT-PCR of BC samples was relatively high, 
except for the decrease that was observed in House A (Table 3). This can be explained by 
the extreme sensitivity of the assay and its ability to amplify the minutest quantities of 
target sequence, for this reason the Biorad MyiQ software calls positives based on 
amplification crossing the threshold and occurring before the negative control plus the 
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tolerance (Biorad, Hercules, CA U.S.A.). When compared to VI, more positive samples 
were in qrRT-PCR. Several postulations can be made to explain these occurrences. Firstly, 
the sensitivity of the VI must be questioned. Referring back to Figure 4, the trend lines of 
both qrRT-PCRs are nearly linear, suggesting that the lower range of detection of qrRT-
PCR is greater than that of VI. If negative values of VI were included in this figure it 
would be expected that the CT values will increase at the lower limits of the assay until 
there is a cessation of amplification. Therefore, what is considered false positive in this 
study may truly be false negative and the ALV present in the sample inoculated into tissue 
culture may have been inhibited by virus neutralizing antibodies. Retroviruses are 
notorious for their capacity to form replication defective particles, which may also 
contribute to this factor (128).  
The extraction method utilized for the development of this assay has been 
compared to other established methods of extraction. The National Veterinary Services 
Laboratory (NVSL) has successfully implemented this extraction technique into their 
Exotic Newcastle Disease virus (ENDV) diagnostic; with over 100,000 samples analyzed 
not a single case of cross contamination or false positive/negative result has been observed 
(48). Data published by Ambion, Inc. further investigated the incidence of cross 
contamination when the extraction procedure was carried robotically using their MagMAX 
technology modified for whole blood samples. A checkerboard pattern was created which 
consisted of 24 positives surrounded by 72 negative samples no amplification was detected 
following total RNA isolation of negative blood samples (47). 
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The samples used for this assay were BC samples which contain the hemapoeitic 
progenitor cells the exogenous ALV subgroups typically infect (109). In addition to 
containing the proviral DNA, the extracellular fluid also has the potential to contain virus 
particles. This sample medium therefore presents two possible routes of target 
amplification, in turn increasing sensitivity. While providing a higher degree of sensitivity, 
this sample type is slightly more labor intensive compared to other cell-free sample types 
such as plasma. BC samples were compared to plasma and similar results were obtained 
(data not shown). When this assay was first undertaken a whole blood or BC extraction 
procedure had yet to be developed. Harsher lysis buffers and integration of proteases will 
make the extraction from these BC samples less labor intensive and therefore a more 
efficient route of exogenous ALV detection. 
We have presented data that provides for a more sensitive, rapid, high-through-put, 
and cost effective means of exogenous ALV detection, providing a practical and efficient 
tool for commercial breeder operations to monitor and eventually eradicate ALV within 
their flocks. This new approach to exogenous ALV detection bridges a gap, allowing the 
full benefits of PCR based technologies to be used in high throughput diagnostic tests. 
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THE E ELEMENT OF AVIAN LEUKOSIS VIRUS SUBGROUP J: ITS EFFECT 
ON PATHENOGENESIS BY PROVIRAL INTEGRATION AND 
DEREGULATION OF C-ERBB AND C-MYC 
 
 
Overview 
 
 The association of neoplastic disease and the deregulation of cellular oncogenes has 
been well characterized. In this study the deregulation of both c-myc and c-erbB mRNA 
was evaluated in commercial broiler chickens inoculated with wild-type and recombinant 
ALV-Js either expressing or lacking the E element within the ALV-J genetic sequence. In 
addition, the quantification of circulating ALV-J copy numbers and the integration of its 
proviral DNA within the chicken genome were investigated. These data were correlated 
and preliminary results suggest that the E element may have a greater efficiency at c-myc 
upregulation. At this point the neoplastic potential and pathogenicity of this region are 
difficult to predict. Further investigation and continuation of the experiment will allow for 
the development of neoplastic disease, greatly enhancing our ability to determine the 
effects of the E element during ALV-J infection. 
Introduction 
 
 Viral upregulation and/or activation of cellular oncogenes has been associated with 
neoplastic formation in many animal models (21, 51, 65), and is commonly involved in 
many human diseases including Epstein-Bar virus, Burkitt’s lymphoma, and prostate 
cancer (92). It was nearly a century ago that the viral etiology of sarcomas and leukemia 
(leukosis) in the domestic fowl was first described by Ellerman and Bang (1908), working 
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in Copenhagen, and Rous (1910) in New York (38, 123). Through the following decades, 
in an attempt to control these oncogenic diseases, which were becoming a significant cause 
of mortality in commercial poultry, extensive investigation in many veterinary laboratories 
was undertaken. Through this period the chicken has been an instrumental tool in 
discovering the mechanisms of pathogenesis of oncogenic viruses. Avian leukosis virus 
(ALV) and Rous sarcoma virus (RSV) have subsequently become the model systems of 
which to elucidate the mechanisms which lead to the formation of virally induced tumors.   
Of particular interest are the ALVs, which are grouped into the Alpharetrovirus 
genus of the family Retroviridae (120). These viruses in chickens are classified into five 
pathogenic subgroups: A, B, C, D, and most recently J (106). Their distinctions arise from 
differences in envelope glycoproteins, virus-serum neutralization tests, virus interference, 
and host range (71). ALVs are known to cause a variety of neoplasms including erythroid, 
lymphoid, and myeloid leukoses (109, 110, 149). These pluripotential neoplasms of ALVs 
cause severe economic losses due to condemnations at slaughter, loss of pedigree birds, 
and tumor mortality. The most recently discovered ALV, subgroup J, was isolated from 
meat-type chickens associated with myleocytomatosis in England in the late 1980’s (105). 
Beginning in the early 1990s the commercial broiler industry was confronted with this new 
subgroup of ALV, when it began causing serious production problems and mortality on a 
global scale (106, 141). The host range of ALV-J encompasses jungle fowl, turkeys, and 
egg and meat-type chickens at all breeding generations, including commercial broiler 
flocks (44, 109). ALV-J was predicted to be a recombinant of exogenous ALVs and the 
EAV family of endogenous avian retroviruses (6). In addition to a foreign envelope gene 
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acquired from this group of endogenous retroviruses, the genome of HPRS-103 the 
prototype of the envelope J subgroup of ALV (105), was found to contain an E element in 
the 3’ non-coding region of it’s genome. This enigmatic element, also know as F2 (14, 79) 
and XSR (145), had only been found in replication competent RSVs, but not in naturally 
occurring, replication-competent ALVs (13, 14). This novel addition to the ALV-J genome 
is of particular interest for several reasons. Firstly, it is predicted that this region is capable 
of forming a hairpin structure that might operate at either the level of DNA or RNA  which 
may explain it’s ability to bind the transcription factor c/EBP (125, 129). Secondly, the E 
element is found 5’ of v-src in RSV SR, but 3’ of v-src in RSV Pr, which presumably 
allows it’s biological function to be exerted over distances of at least 1800 nucleotides 
(129). By analogy, it has been speculated (129) that this E region may be a transcriptional 
enhancer sequence, since the 72 bp murine leukemia virus enhancer sequence  is capable 
of forming a strong hairpin structure  and since enhancers can operate over long distances 
(9, 23, 80). This unique combination of characteristics has also been speculated to play a 
role in ALV-J oncogenesis, in particular, functioning as a promoter or enhancer within B 
cells (85). Upon studies to determine the pathogenicity of two recombinant ALVs Lupiani 
et al. (85) found there to be significant differences in oncogenic potential between two 
viruses, one of which was lacking the E element, leading to the speculation of a possible 
role this region may play in pathogenicity. Several ALV-J strains have been isolated 
globally with differences in the E element region, when compared to the prototype HPRS-
103 strain; however comprehensive studies focused on determining the effects of these 
mutations within the ALV-J genome have yet to be performed (34, 142).   
53 
 
 Oncogenesis initiated by ALV-J infection is predominantly found in the form 
myeloid leukosis (ML) (myleocytomatosis) (109), a characteristic thought to be associated 
with its ability to replicate well in blood monocyte cultures but less so in the lymphoid 
follicles of the bursa of Fabricius (2). Its ability to transform cells of the myeloid lineage 
are a direct consequence of its proviral integration next to the cellular proto-oncogene c-
myc, subsequently enhancing and/or promoting the transcription of the oncogene via action 
of its long terminal repeat (LTR), resulting in the development of monoclonal tumors (55, 
64). In experimentally infected embryos or 1-day-old chicks the development of bursal 
lymphomas will occur in approximately 50% to 100% of lymphoma-susceptible chicks by 
this method of cellular oncogene upregulation (20, 50).  This transcription factor controls 
cell functions such as proliferation, differentiation, and apoptosis, through activation and 
repression of a number of target genes (58). These Myc regulated genes include those 
involved in angiogenesis, metabolism, and cell cycle and growth (28, 90). The over 
expression of Myc has also been shown to inhibit cellular differentiation, perhaps through 
its ability to block the cell cycle exit (65). In addition, Myc can also sensitize cells to 
apoptosis  and it effectively induces blood vessel growth in a number of tumor models (17, 
89, 93, 113). Examination of the proviral integration within these neoplastic lymphoid cells 
show that nearly all proviruses have under gone deletion of the 5’ LTR (82, 83), in turn 
allowing the 3’ LTR to more efficiently induce high levels of c-myc gene transcription 
(75).  
 ALV has also been shown to induce erythroblastosis by mechanisms similar to 
those which cause ML, by integration of proviruses near another host oncogene, c-erbB.  
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This cellular oncogene was first discovered due to its close amino acid homology with 
portions of the human epidermal growth factor receptor (EGF) which were strikingly 
similar to the oncogenes carried by the acutely transforming avian erythroblastosis virus 
(AEV) (147, 152). Data has shown that upon activation, c-erbB can assume an oncogenic 
role similar to that of its viral counterpart.  The c-erbB oncogene encodes the EGF 
receptor, a protein kinase which is involved in growth signaling in many cell types, 
hemopoiesis, and formation of transforming growth factor α (TGFα) (95, 100, 104).  The 
EGF receptor contains three domains, an extracellular EGF binding domain, a short 
transmembrane domain, and a  cytoplasmic domain (70). Interestingly, upon ALV 
infection most of the proviral integrations from tumors map within the 3’ region of c-erbB 
intron 14, so that a truncated gag-env-erbB fusion protein is produced which is thought to 
have constitutive kinase activity (46, 86, 95, 118).  From these fusion products and in turn 
read-through transcripts, recombinant viruses arise containing transduced c-erbB, forming 
acutely transforming viruses which can be observed in approximately 50% of the 
erythroblastosis tumors that arise (86, 95).  Of those proviruses analyzed after initial 
infection, all were inserted in the same transcriptional orientation as c-erbB, and elevated 
expression of c-erbB related mRNA was consistently observed (51, 118). Raines et al. 
observed that the truncated, structurally altered transcripts of c-erbB show a 100% 
correlation with the development of erythroblastosis, suggesting that disruption of the c-
erbB locus is important for oncogenesis (114, 115, 118). 
 As described, examinations of ALV proviral integration sites within the c-myc or c-
erbB genes of tumors has revealed a non-random pattern of proviral integration, giving 
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insight to the oncogenic mechanisms of ALV. The integration of the ALV proviral DNA 
into c-myc has been shown to cause bursal lymphomas, and predominantly this insertion 
occurs within the 3’ region of c-myc intron 1 (122, 130). With the c-myc protein-coding 
sequence beginning in exon 2, the promoter/enhancer capabilities of the ALV LTR 
sequence have been shown to increase c-myc mRNA and protein roughly 50-fold (87). The 
integration of c-erbB observed in erythroblastosis are also non-random, so that the majority 
of tumors show integrations clustered within the 300 bp region of intron 14 (55).  
There are many aspects of this ALV-J which remain to be elucidated. The research 
presented here will attempt to shed light on the role played by the E element during ALV-J 
infection. By quantifying viremia via quantitative real-time (qr)RT-PCR we will determine 
the effects of the E element on replication efficiency, a factor possibly altered by this 
region of the virus that has yet to be studied. In addition, we will also determine the levels 
of the oncogenes c-myc and c-erbB transcribed throughout the course of infection and 
correlate this data to viral load.  ALV-J viremia and its outcome on virally induced 
oncogenesis both with and without the E element is an additional aspect which will be 
analyzed throughout this study. By combining this data and correlating the levels 
circulating ALV-J, c-myc, and c-erbB we aim to better demonstrate the role of the E 
element during ALV-J infection.  
Materials and methods 
     A. Viruses 
 All viruses and molecular clones utilized in this study were kindly provided by Dr. 
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Blanca Lupiani (Texas A&M University / College of Veterinary Medicine). A detailed 
description of the origins and development of these viruses are discussed. 
 A field strain of ALV-J, R5-4, initially isolated by the Avian Disease and Oncology 
Laboratory (ADOL) served as the parent strain (ADOL R5-4) of ALV-J virus in this study 
(84). Using standard methods proviral DNA of ADOL R5-4 was molecularly cloned to 
form pALV-J. Briefly, DF-1 cells were inoculated with the ADOL R5-4 strain of ALV-J. 
Seven days post inoculation, DNA from infected cells was purified, digested with NotI and 
a library generated as described (126).  Clones containing ALV-J sequences were 
identified by plaque hybridization using oligonucleotide probes corresponding to the viral 
LTR and env gene. Once the full length clone was identified, host DNA sequences 
flanking the proviral DNA were eliminated as follows. The clone was digested with ApnLI 
(a restriction enzyme that recognizes unique sites in both viral LTRs) re-ligated to itself to 
form circular molecules, digested with KpnI (a unique restriction site located upstream of 
the env gene) and ligated to a pBS SK+ plasmid digested with KpnI.   
 In order to generate a molecular clone with two LTRs, the 5’ LTR and UTR were 
PCR amplified with a forward primer, containing a SpeI site, complementary to the 5’end 
of the LTR and a reverse primer complementary to the BstEII site of the 5’ UTR. 
Similarly, the 3’ UTR was PCR amplified with a primer complementary to the Bsu36I site, 
located in the 3’ UTR, and a reverse primer, containing a unique NotI site, complementary 
to the 3’ end of the LTR. These PCR products were ligated to the rest of the viral genome 
using the BstEII and Bsu36I restriction sites generating a molecular clone identical to the 
proviral DNA (pALV-J) (Figure 5). This process generated the molecular clone of the R5-
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4 isolate (pALV-J/kpnI) with a single LTR (Figure 5). The pathogenicity of pALV-J was 
tested in meat-type chickens; day-old chicks were inoculated with 105 TCID50 at hatch. 
Inoculated chickens tested positive for ALV-J viremia and developed tumors within 30 
weeks of age, confirming pALV-J to be infectious (84).  
  
Figure 5. Schematic representations of two recombinant ALV-J viruses: pALV-J/KpnI and pALV-J. 
A. Schematic representation of the molecular clone, created by Katherin Conklyn from the original 
isolate R5-4; B. A easily manipulated plasmid vector pALV-J containing intact infectious ALV-J with 
multiple splice sites identified. 
In order to generate a pALV-J virus without the E element (pALV-J /∆E) the ALV-
J 3’LTR was PCR amplified from pALV-J using a forward primer containing a Bsu36 I 
site overhang (underlined) (Bsu36-EI 5’ CCC TCA GGA TAT AGT AGT TGC GCT TTT 
GCA TAG GGA GGG GGA 3’) immediately downstream of the E element and a reverse 
primer with a Not I site overhang (underlined) (J-LTR.3 5’ CAA GCG GCC GCT AAT 
GAA GCC ATC CGC 3’) complementary to the 3’-end of U5.  The PCR product obtained 
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was then subcloned into the pALV-J vector using Bsu36I and NotI restriction sites, 
yielding the virus pALV-J /∆E (Figure 5). 
     B. Experimental design 
One-day-old commercial broiler chicks were randomly selected and placed into 4 
treatment groups: one serving as a negative control inoculated intra-abdominally with 
0.1ml PBS, while the others were inoculated intra-abdominally with an equivalent volume 
buffered cell culture supernatant containing 103.5 infectious units of the three described 
ALV-Js (ADOL R5-4, pAVL-J, and pALV-J /∆E), receptively. Each group consisted of 22 
chickens that were kept in isolation until the termination of the experiment. For individual 
identification purposes the birds were wing-banded according to their respective treatment 
and given number designations of 1-22. Those birds that lost wing bands during the trial 
were recorded as “no band” (NB) and data for these birds was not utilized. Liver, spleen, 
brain, kidney, marrow, and tumor tissue (if present) were collected and preserved in a 1:5 
(vols/vols) ratio of RNAlater (Qiagen; Valencia, CA). For the purposes of this manuscript 
data will be interpreted from chickens that were sampled at 1, 5 and 11 weeks post 
inoculation (PI).  
Samples were tested for viremia, c-myc, c-erbB, and glycerolaldehyde 3-phosphate 
(GAPDH) gene expression via qrRT-PCR. Chickens were also observed for tumors 
throughout the experiment, until termination. Chickens that were incapacitated and/or 
unresponsive were euthanized via CD. Samples of blood (when possible) and affected 
tissues from mortalities and euthanized chickens were collected for use in gene expression 
assays and preserved in RNAlater (1:5 dilution) (Qiagen; Valencia, CA). Additional tumor 
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tissues from necropsied chickens were fixed in 10% buffered formalin, stained with 
hematoxylin and eosin, and examined for ALV-J induced microscopic lesions.   
     C. Sample and tissue preparation from experimental chickens 
 At selected time points throughout the trial (at 0 and every odd numbered week) 
approximately 0.75 ml of blood was drawn from all birds of each treatment and dispensed 
into 2 ml Vacuette® tubes coated with EDTA K3 specific to each bird of each treatment. 
Subsequently, the samples were centrifuged (2000 rpm for 5min) and aliquoted out as 
follows: 2 rows (1-24 wells) of a 96 well plate were designated for each treatment, samples 
from each chicken (1-22) were placed into their respective well, while the 23rd and 24th 
wells severed as controls (extraction and qrRT-PCR). Dispensed into the wells of three 
respective plates were: 50 µl of plasma for viral (v)RNA extraction, 160 µl of plasma for 
future use, and 20 µl of BC preserved in 180 µl of RNAlater (Qiagen; Valencia, CA) for 
quantification of viremia, the housekeeping gene (GAPDH), and the oncogenes c-myc and 
c-erbB. To corroborate the results of qrRT-PCR a 48-well tissue culture plate was divided 
in two sections and 100 µl of plasma was aliquoted in duplicate from each bird for each 
treatment into its respective well, to be used for virus isolation (VI). Immediately 
following this processing, plates were sealed with adhesive covers and stored at -80oC till 
extraction or VI procedures were carried out.  
D. RNA isolation  
vRNA was extracted from 50 µl plasma samples in a 96-well plate format with the 
use of nucleic acid-binding magnetic particles supplied by the MagMAXTM Viral RNA 
Isolation Kit developed by Ambion®, Inc. (Austin, Texas, USA). The manufacturer’s 
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protocol for cell free sample was followed.  
 Total RNA (cellular and viral) was extracted from BC samples utilizing a modified 
protocol of the MagMAXTM kit (Ambion® Inc., Austin, Texas). The manufacturer’s 
protocol was optimized. Briefly, the preprocessed 96-well plates containing 20 µl of BC 
and 180 µl of RNAlater (Qiagen; Valencia, CA) were centrifuged at 2500 rpm for seven 
minutes to pellet the cells. The residual RNAlater (Qiagen; Valencia, CA) was aspirated 
and 100 µl of the MagMAXTM Lysis/Binding Solution was added and the plate was then 
shaken on a DPC MicroMix® 5 (form 4, amplitude 18) for 5 min. The cellular debris was 
then pelleted by centrifugation at 2500 rpm for 5 min at 4oC. Following centrifugation 
approximately 80-90 µl of the Lysis/Binding Solution (avoiding the carryover of cellular 
debris) was transferred to a new 96-well plate. Twenty µl of the MagMAXTM Bead 
Suspension Solution was then added to each well and shaken as previously described. 
Following this step the magnetic particles were pelleted with 96-well Magnetic Ring-
Stand, the residual Lysis/Binding Solution was aspirated, and 20 µl of DNAse I (1U to 
1000 µl DNAse I buffer dilution) was added, shaken (form 5, amplitude 19) for 5 min and 
followed by a 15 min incubation at 37oC. Following the incubation, 100 µl of the 
Lysis/Binding Solution was added and shaken as described initially. This step was 
followed by a series of wash steps as described in the manufacture’s protocol. Finally, total 
RNA was eluted in 30µl of the supplied elution buffer.  
 Tissue samples were extracted in much the same way. Residual RNAlater (Qiagen; 
Valencia, CA) was aspirated and approximately four volumes (0.1g tissue:0.4ml) of the 
MagMAXTM Lysis/Binding Solution was added the sample in a 1500 µl microcentrifudge 
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tube and pulse sonicated for ~5 sec. The tube was then vortexed, agitated for 5 min, and 
centrifuged at 8000 rpm for 2 min. Lysis/Binding Solution free of cellular debris was then 
transferred to clean tube, followed by the total RNA extraction method described above, 
for the exception of the tube format. 
     E. Primer design 
 The mRNA sequences of c-myc, c-erbB, and GAPDH were obtained through 
GeneBank (Table 5). The design of primers and probe sets was aided by the use of the 
PrimerSelect program within the DNASTAR software package (DNASTAR, Inc., USA) to 
comply with TaqMan criteria (18). Each primer pair was selected to have a maximal Tm 
difference of less than 2oC, a GC content between 20% and 80%, no GC clamp, a length of 
between 9 and 40 nucleotides, fewer than 4 repeated G residues per primer, no hairpins 
with a stem size of less than or equal to 4, and an amplicon size of between 50 and 150 bp. 
When possible TaqMan probes were designed to have a Tm 10oC greater than that of the 
flanking primer pairs, no G at the 5’ end, and positioned over a splice site within the target 
sequence. Splice sites were determined by analysis of the chicken genome whole transcript 
products (Genebank, NCBI).     
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Table 5. Primers and probe sets and their location. AChicken epideremal growth factor receptor 
mRNA (accession #NM_205497). Bc-Myc chicken oncogene mRNA (accession # X68073). 
CGlycerolaldehyde-3-dehydrogenase chicken  mRNA (142). DE element region, avian leukosis virus 
subgroup J genome HPRS-103 (accession #Z46390). 
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     F. Exogenous control RNA development   
In an effort to reduce possible contamination resulting from the transfection and 
creation of plasmid vectors containing the dsDNA target sequence, control RNA sequences 
were developed employing PCR techniques. A forward primer was developed which 
contained an overhang of the T7 polymerase recognition sequence on its 5’ end, resulting 
in a primer of 40 bp, 22 of which were the T7 recognition sequence. The reverse primer 
was then created to amplify a region which spanned multiple splice sites, allowing for the 
use of the same control sequence for the development of multiple primers and probe sets if 
they were required. Using the methods of total RNA extraction previously described a RT-
PCR reaction was performed in a 50µl reaction volume, which included 25 µl Qiagen RT-
PCR Probe MasterMix, 16.5 µl nuclease free water, 1.5 µl of both 10µM forward and 
reverse primers, 0.5 µl RT, and 5 µl eluted RNA product. The PCR reaction included a 30 
min RT step @ 50oC followed by a 15 min denaturation step at 95oC. The amplification 
cycles included three steps: 1) 95oC for 30 sec, 2) an annealing gradient spanning from 
55oC to 65oC for 45 sec, 3) and a final extension step at 70oC for one min. Agar gel 
electrophoresis (AGE) was carried out with 5 µl of this product to determine successful 
amplification and the annealing temperature which most efficiently amplified the control 
sequence. The two tubes containing the most target sequence, determined by band intensity 
of AGE, were PCR purified (Qiagen, Valencia, CA). This DNA product was then 
transcribed with the Promega T7 RiboMax kit according to the manufacture’s protocol. 
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 G. Virological and gene expression assays   
 Blood and tissue were processed as previously described from experimentally 
infected chickens as well as uninoculated controls and tested for viremia, c-myc, c-erbB, 
and GAPDH by quantitative real time RT-PCR (qrRT-PCR) as previously described (88). 
Breifly, seven microliters of eluted RNA sample was added to a mixture containing 12.5 µl 
of Qiagen QuantiTech® MasterMix, 3.5µl of water, 0.5µl of each primer (10µM), 0.5µl of 
probe (5µM), and 0.25µl RT,  yielding a 25µl qrRT-PCR final reaction volume. ALV-J 
RNA copy numbers were extrapolated using data obtained from a standard curve of six log 
dilutions. Gene expression of c-myc and c-erbB was measured via qrRT-PCR with the 
same RNA and qrRT-PCR reagents used for quantifying viremia, with exception of the 
different primers and probe sets (Table 5). 
     H. Relative quantification of gene transcription 
 Current data has shown that GAPDH mRNA levels were found to show the least 
standard deviation when compared to chicken telomerase RNA and chicken telomerase 
reverse transcriptase (143). In concordance with this data all levels of gene expression and 
viremia were normalized to the housekeeping gene GAPDH by averaging the CT values of 
this transcript for each sample of every plate. This value was then used to derive a standard 
deviation (SD), the difference of any GAPDH CT value outside the range of the SD was 
applied to the respective well of each qrRT-PCR to normalize CT values, correcting for any 
inconsistencies in the extraction process.  
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   I. acELISA 
 In addition to qrRT-PCR, BC and plasma samples were inoculated onto cell culture 
to determine the presence of ALV-J by detection of p27 antigen. Briefly, 100µl of sample 
was simultaneously inoculated onto 48-well tissue culture plates containing 1.5x105 DF-1 
cells per well in 4% growth medium, containing 3.76 g Leibovitz L-15 Medium, McCoy’s 
5A Medium Mix, 1.1 g NaHCO3, 20 ml (4%) fetal bovine serum (FBS), 1 mg 
amphotericin B, 12.5 mg gentamycin, 1 mg DEAE dextran, 2000 units of heparin, and 
brought to a volume of 500 ml. Following 24 hr incubation the media was removed and 
replaced with maintenance media (1% FBS growth media without DEAE dextran and 
heparin) and incubated for an additional 7 days.  Plates were then processed for p27 
antigen by the addition of 50µl 5% Tween 80 to each well followed by two freeze-thaw 
cycles. One hundred-microliter aliquots of cell lysates were collected from each well and 
transferred to 96-well plates for acELISA detection. ALV acELISA assay protocol and 
readings were performed according to the manufacture’s recommendations (IDEXX 
Laboratories, Westbrook, ME) except a sample to positive ratio (S/P) cutoff value of 0.1, 
less stringent than the manufacture’s recommendation of 0.2, was used to call positives. 
S/P ratios were calculated by subtracting the negative control mean absorbance value at 
650 nm, A(650), from the sample mean and dividing this value by the value obtained from 
subtracting the negative control mean at A(650) from positive control mean at A(650).  
{[(sample mean – negative control mean) / (positive control mean – negative control 
mean)] = S/P} 
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Results  
A. Propagation of viruses 
 Viruses pALV-J, ADOL R5-4, and pALV-J /∆E were propagated in DF-1 cells. 
Confirmation of virus presence and titer was determined by qrRT-PCR and acELISA, 
repectively. Cell culture supernatants containing the respective viruses were diluted to 
contain 103.5 infectious particles per 0.1 ml with buffered cell culture media. Presence or 
absence of the E element was verified by PCR followed by AGE of infected DF-1 cellular 
DNA using the forward primer 5’-ACT TCC ACC AAT CGA CGT GT-3’ and reverse 
primer 5’-AAT GGG GCA ATG TAA AGC AG-3’ (Table 5). These primers spanned a 
400 bp region encompassing the E element. Positive conformation of the missing E 
element was observed via AGE by 150 bp reduction in the size of the pALV-J /∆E 
amplicon, when compared to those of ADOL R5-4 and pALV-J. Outliers were corrected 
for each treatment and time point, retaining the central ~75% of the data points: all data 
analyzed for GAPDH at each time point was sorted by CT value and the outer most data 
points were removed, this same method was carried out for c-myc expression levels, and 
finally ALV-J CT values, leaving 16 data points for each treatment.  
B. ALV-J-induced viremia and deregulation of cellular oncogenes 
 Levels of circulating ALV-J determined by qrRT-PCR beginning with week one 
for all treatments were relatively low to non-existent, with the exception of pALV-J, which 
had copy numbers greater than 25 times that of the nearest virus, pALV-J (Figure 6). The 
circulating levels of pALV-J remained elevated through the trial and averaged 135% 
greater viremia than did pALV-J/∆E, its closest counterpart. Levels of virus measured in 
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the negative control treatment calculated to be less than one copy per microliter, out of the 
linear range of the qrRT-PCR assay. While the level of pALV-J was substantially higher 
than the other treatments during week one, these levels reduced as the experiment 
progressed (Figure 6).  
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Figure 6. Normalized viremia levels in chickens challenged with pALV-J/∆E,  
 pALV-J and ADOL R5-4. 
 The expression of c-myc transcripts increased throughout the experiment, yet 
stayed relatively proportional to the negative control (Figure 7). The levels of c-myc gene 
expressed between the negative control and the pALV-J/∆E treatment were nearly 
equivalent throughout the period of the trial, and averaged 28.4% greater than did c-myc 
expression in chickens infected with the pALV-J and ADOLmcPr5-4 viruses. 
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Figure 7. Normalized c-myc levels in chickens challenged with pALV-J/∆E, pALV-J and ADOL R5-4. 
 
 
 As was previously shown, the levels of GAPDH expression were extremely 
constant over the course of infection (143). The range of variance was 1.1 CT, averaging 
2.6 SDs (Figure 8). A steady but slight increase was observed however, ranging 3.1 CTs 
over the data presented. The negative control and the pALV-J/∆E infected treatments were 
consistently elevated over the values observed in the other two treatments (Figure 8). 
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Figure 8. Normalized GAPDH expression in chickens challenged with pALV-J/∆E, pALV-J and ADOL 
R5-4. 
 
 
 Configuration of the data to portray mRNA expression of the five chickens 
expressing the highest viremia showed steadily increasing levels of c-myc throughout the 
course of infection in those birds infected with experimental viruses, while expression 
levels in the negative control group remained relatively constant (Figure 9). 
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Figure 9. c-myc expression in 5 chickens expressing the highest viremia levels in  
     chickens challenged with pALV-J/∆E, pALV-J and ADOL R5-4. 
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Results presented in this format also showed GAPDH levels consistent with those 
observed in normalized values (Figure 10). The levels of viremia in those five birds with the 
highest circulating ALV-J also showed similar levels of circulating virus as those seen in 
the normalized data (Figure 11). 
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Figure 10. GAPDH expression in chickens expressing 5 highest levels of viremia  
       levels in chickens challenged with pALV-J/∆E, pALV-J and ADOL  
       R5-4. 
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Figure 11. Viremia values in 5 chickens expressing the highest viremia levels in  
       chickens challenged with pALV-J/∆E, pALV-J and ADOL R5-4 
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C. Experiments in progress 
  This study remains ongoing and future work includes the incorporation of 
additional data points through a minimum of 30 weeks total, in addition to analyzing 
samples at time points within the span presented here. The expression of c-erbB data was 
not presented due to inefficient amplification of the target sequence. Prior to the production 
of control RNA, preliminary qrRT-PCRs utilizing extracted totRNA from chicken tracheal 
tissues resulted in satisfactory amplification. Further development of the control sequence 
revealed that lower limit of detection of the primers and probe set developed was 
approximately 104 copies. Two time points were analyzed by qrRT-PCR for c-erbB (Table 
5), week one yielded three positive samples and week 5 yeilded no positives, at this point 
detection of c-erbB transcripts has been postponed until a more optimal set of primers and 
probe can be developed. In addition to the quantification of c-erbB expression, samples 
will also be isolated in cell culture and then analyzed via acELISA for ALV p27. 
Discussion 
 Although the data presented do not completely support the hypothesis, certain 
trends can be observed and continuation of the experiment may lead to more definitive 
results. For instance, the high levels of pALV-J expressed early in infection are consistent 
with high numbers of replicating virus and in turn integrating virus. As the experiment 
progressed the circulating levels of this virus were cleared to levels similar to that of the 
other viruses. Yet, as copy numbers of this virus decreased, an almost proportional 
increase in c-myc mRNA expression was observed. This increased expression could be 
speculated to be caused by the integration of proviral DNA early during infection, resulting 
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in the increased c-myc transcription later. Further time points may reveal similar 
circumstances for pALV-J, as observed in week 5 increased replication lead to increased c-
myc expression. However, the levels of c-myc transcript expression observed in the 
negative control counter the validity of the above arguments. Although, further 
investigation may reveal a plateau of c-myc expression that may be reached upon 
maturation of the chicken (18-20 weeks). ALV-J positive birds in this case may continue to 
show increasing amounts of c-myc as clonal replication within tumor tissue occurs.  
 The circulating levels of virus presented here differ from the conventional 
reasoning of ALV-J replication in chicks deficient of a mature immune system. In most 
scenarios infection at an early age leads to recognition of ALV-J as “self” and therefore the 
chick will not mount an immune response, producing no virus neutralizing antibodies 
allowing the virus to replicate unabated. The results here do not directly show this, 
however in some instances chicks may develop an immune response and clear or reduce 
circulating virus. This speculation can be tested with conventional, commercially available 
ELISA kits able to detect the anti-SU antibodies. Detection of these antibodies could 
explain the reduced viremia over the course of this experiment. If antibodies are present, 
this does not explain the substantial difference between the replication efficiencies of 
pALV-J and ADOL R5-4. It may be hypothesized that there are differences in the 
antigenic structure of their envelope glycoproteins. Even though ADOL R5-4 was the 
original isolate used to produce the molecular clone, pALV-J, sequencing should be 
performed to ensure have been sequenced their genetic similarity. 
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 If the data is sorted and arranged based according to viremia levels and chickens in 
the top quartile of circulating ALV-J copy numbers are selected the data reveals c-myc 
levels more characteristic of the hypothesized scenario following ALV infection (Figure 9). 
Firstly, the negative control treatment’s expression of c-myc transcripts is steady over the 
sample period and at week 1 data levels are relatively similar, with the exception of 
slightly increased pALV-J/∆E copy numbers. This data configuration also shows the 
extreme level of amplification of ADOL R5-4 within this first week, when compared to the 
other treatments (Figure 11). The upregulation c-myc remains clearly distinguishable from 
the other viruses. Chickens infected with pALV-J/∆E also show an upregulation of c-myc 
above the negative control. However, clear differences in the pathogenicity of this 
recombinant are difficult to distinguish. Further time points and analysis of tumor tissue 
will help further elucidate the role in pathogenicity this portion of the ALV genome. 
 The deregulation of c-erbB will be an important aspect of measurement to better 
understand and elucidate the functions of the E element. While the analysis of c-erbB 
upregulation was not successful in this phase of the experiment, the amplification of this 
region by qrRT-PCR was carefully plotted and significant time was spent isolating a 
specific amplicon. The initial unprocessed transcript, containing introns, is approximately 
120kb, within this region are 12 exons coding for the epidermal growth factor receptor. In 
order to detect only processed functional c-erbB transcripts, all splice sites within the 
region were identified and these regions served as the basis for development of primer sets. 
Probes were first developed to span these splice sites, in order to eliminate or reduce the 
incidence of probe binding to unprocessed non-functional c-erbB. Upon the creation of 
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these probes, which was carried out both manually and with the aid of the PrimerSelect 
program supplied in the DNASTAR software package, selection of viable candidates was 
made based on Tm, ∆G values, and placement within the transcript. Past studies have 
revealed that upregulated c-erbB transcripts are structurally altered and often result in 
fusion products containing the 3’ end of the c-erbB transcript. Based on these viable 
candidates, primer pairs were then developed to flank these regions. The use of currently 
available software provided little support in the development of these primers and their 
respective probe due to the extremely specific placement necessary to provide accurate 
quantification of the target gene. Alternative primer and probe sets have been developed 
and will be evaluated for their sensitivity. 
 The E element remains an enigmatic portion of the ALV genome. However, with 
further investigation, especially following the induction of tumors, our goal is to shed light 
on this elusive region, determining its role, if any, in pathogenicity. If found to cause 
increased formation of neoplastic disease, or increased replication efficiency as this 
experiment continues, or some other form of increased pathogenicity this information 
could potentially be used to determine other similar endogenous cytopathic factors 
produced by humans or animal species. In the case that this region is a factor in ALV-J 
pathogenicity, investigations into the mechanisms by which its able to cause the increased 
pathogenicity could potentially lead to novel therapeutics to treat other oncogenic diseases. 
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DISCUSSION AND SUMMARY 
Overview  
 Retroviruses and their association with neoplastic disease have been described in 
the literature for nearly one century. Throughout this period a vast number of creative 
individuals have shed light on the elusive elements that form the mechanisms of their 
disease. Today the family Retroviridae encompasses a total of seven unique genera whose 
diseases are most often associated with the induction of cancer or immune deficiencies.  
 ALV, a member of the Alpharetroviruses, is an economically significant virus to 
the poultry industry. The disease incited by this virus within the chicken is known to cause 
a variety of neoplasms, which result in decreased production traits, condemnations at 
slaughter, and tumor mortality. The pathogenic forms of this ALV are classified into five 
subgroups, those being A, B, C, D, and J. Subgroup J ALV, the most recently of the ALVs 
to be discovered, became a significant economic threat to the commercial broiler industry 
soon after its identification (105). The efficiency at which ALV-J is able to spread 
facilitated its rapid global dissemination throughout meat-type poultry flocks. This virus 
had and remains to have its most profound effects on the primary breeder industry, which 
was impelled to implement eradication schemes to control this novel subgroup, leading to 
detrimental losses to pedigree stocks. 
Diagnostic development 
The pluripotent neoplasms induced by exogenous ALV infection have led to 
significant economic losses in the commercial broiler industry worldwide, primarily as a 
result of the introduction of ALV-J to pedigree stocks. The original isolation of the novel 
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subgroup was made in 1988 during a survey of ALV infection among breeding stock in 
England (105). By the early 1990s the commercial broiler industry was adopting 
eradication programs in an effort to control ALV-J. Optimization of current ALV 
diagnostic techniques of the time resulted in a ‘gold standard’ assay, still employed today 
by the majority of the industry. ALV-J arose by recombination of an unknown exogenous 
ALV and the envelope domain of an ev loci (11); as a result, the predominant gs antigen 
produced by ALV-J was p27, a protein also translated from ev derived transcripts. The 
ubiquitous ev loci, p27, circulates among nearly all lines chickens, requiring that the 
diagnostic for exogenous pathogenic ALV account for and/or eliminate the detection of 
endogenously produced p27. The resulting assay first employed isolation and growth of 
virus in cell culture free of endogenous viral transcripts for a minimum of seven days, 
followed by detection of the exogenously produced p27 protein via acELISA. 
 This method of exogenous ALV-J detection is time consuming, laborious, 
expensive, and is dependent on the presence of infectious virus. With methods to control 
ALV primarily focused on its eventual eradication the industry required a diagnostic that 
could provide a rapid, sensitive, and cost efficient method of detecting this virus. The 
existing gold standard allows ample time for the horizontal transmission of virus to 
littermates and continued vertical transmission by breeders, inciting a chain of infection 
that would be nearly impossible to break without detrimental consequences to breeding 
stock.  However, with the advent of molecular based diagnostic techniques and real-time 
high throughput analysis tools, eradication became a more realistic goal. In an effort to 
provide, for the commercial poultry industry, an ALV diagnostic that could fulfill the 
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above mentioned criteria, a qrRT-PCR assay for the detection of exclusively all exogenous 
ALV subgroups was developed. An RNA isolation technique commercially available 
through Ambion Diagnostics® was incorporated into the assay to facilitate the high 
throughput capabilities required, in addition to RT-PCR technology able to provide rapid 
results in real-time. The resulting assay isolated totRNA from BC samples in a standard 
96-well plate, producing the input for a qrRT-PCR reaction. This single-tube qrRT-PCR 
assay utilized a hydrolysis fluorogenic probe for the specific detection and quantification 
of only exogenous ALVs able to rapidly identifying positive samples, in turn expediting 
the removal of infected birds and limiting horizontal and vertical transmission and 
improving the likelihood of exogenous ALV eradication from commercial poultry. 
The role of the E element of ALV-J throughout infection  
 In addition to the foreign envelope gene acquired by ALV-J during recombination, 
a little described region previously only known to exist in RSV and referred to as the E 
element was discovered in the 3’ non-coding region of the ALV-J genome (105). The 
implications of this enigmatic region have yet to be directly studied during viral infection, 
but implications to its role in pathogenicity have been speculated (85). Giving merit to 
these speculations are several physical characteristics of this region, computer modeling 
predicts the capability of this region to form a hairpin structure that might operate at either 
the DNA or RNA level, possibly explaining it’s ability to bind the transcription factor 
c/EBP (125, 129). Secondly, the E element is found 5’ of v-src in RSV SR, but 3’ of v-src 
in RSV Pr, which presumably allows it’s biological function to be exerted over distances 
of at least 1800 nucleotides (129). By analogy, it has been speculated (129) that this E 
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region may be a transcriptional enhancer sequence, since the 72 bp murine leukemia virus 
enhancer sequence  is capable of forming a strong hairpin structure  and since enhancers 
can operate over long distances (9, 23, 80).  
 Results of this study are still in the preliminary stages, however the data obtained to 
this point show trends which, if continue to develop, will give a better understanding of the 
functions of the E element. Currently, trends are being observed that show high levels of 
ALV-J copy numbers, early during infection, lead to higher and more rapid up regulation 
of c-myc transcripts. Data presented to this point concerning the replication efficiency of 
each virus is difficult to interpret; two relatively identical viruses (pALV-J and ADOL R5-
4) are producing very different results, both in the capability to deregulate c-myc and 
especially concerning their replication efficiency. The isolation of the initial R5-4 strain 
from the field, and the resulting quasispecies population, may be a factor in the observed 
differences. Following completion of the experiment representative virus from each 
treatment will be sequenced, once again, and mutations within their genomes analyzed to 
possibly explain the observed differences. Analysis of tumor tissue will yield important 
information concerning the region of ALV proviral integration; observation of proviral 
integration sites via PCR will provide valuable data as to the efficiency by which a 
recombinant ALV with or without the E element will site specifically integrate into or near 
host oncogenes.  
 Aspects of the E element presented here monitor the key points of ALV 
pathogenesis throughout the course of infection, specifically replication efficiency of the 
virus (viremia), its effect on the deregulation of the two oncogenes c-myc and c-erbB (in 
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future) correlated to the induction of neoplastic disease. In addition to the quantification of 
transcribed oncogene products and vRNA via qrRT-PCR, the integration of proviral DNA 
within those cells transformed by ALV-J will be investigated.   
Future directions of ALV-J research 
 Techniques developed and data presented within the pages of this thesis add to the 
current, ever-expanding understanding of this economically important virus. The 
diagnostic technique developed here, if adopted and effectively implemented into 
commercial industry practices, stands to be a critical tool in the eradication of ALV from 
commercial poultry. The E element is an obscure portion of the ALV genome which has 
been speculated to be a factor in pathogenicity (85). The experiments presented here aim to 
decipher what roles the E element may play in ALV-J pathogenicity, with particular 
interest being paid to viremia, deregulation of the oncogenes c-myc and c-erbB, and 
determination of proviral DNA integration sites within the chicken genome.  
 Methods used to bring ALV subgroups A & B under control have been supported 
by the knowledge of the cellular receptor(s) used by the virus to gain entry into the host 
cell, by enabling the selection of chicken lines which lack the specific receptor(s). In the 
same manner, elucidation of the cellular receptor of ALV-J is an important and still elusive 
goal in its eventual eradication. This knowledge would allow scientist to select for and 
possibly genetically engineer chicken lines resistant to ALV-J.  
 Genetic engineering holds unlimited potentials for not only the poultry industry, in 
terms of ALV-J, but for all viruses and for aspects of life. The history of mankind has been 
marked by a series of revolutions beginning with agriculture and recently that of the 
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computer. In every case the introduction of these new technologies was met with some 
form of resistance, this period of skepticism was eventually followed by an acceptance 
within the populations. Today we are on the fringes of a genetic revolution; the genetic 
code to almost all forms of life can be, have been or are being described everyday. While 
this code may today be easy to extract from any organism, translating this code into useful 
information is extremely time consuming and difficult. As science progresses we are 
continually stepping closer to elucidating what all of the all the code means, forming the 
detailed pages of a blueprint that is life. Today much of this technology and its potential 
uses are not accepted by the populations of the world. Much like there was skepticism to 
the revolutions of the past, there will be, and currently is, reluctance to accept the idea of 
gene manipulation.  But as science inches closer to solving this intricate puzzle and more 
information about the positive potentials of gene therapy surface, it is my opinion that the 
population will slowly begin to gain acceptance for this revolutionary means of treating 
infection and disease, therefore giving scientists an unlimited number of options to control 
this economically devastating virus.  
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